Novel substituted fluorinated n-propyl-pyrrolidine compounds, methods for their preparation and therapeutic uses thereof

By developing novel fluorinated N-propyl-pyrrolidine derivatives, the problems of suboptimal pharmacological properties and CYP3A4 induction limitation of existing SERD compounds in breast cancer treatment have been solved. This has enabled effective estrogen receptor inhibition and degradation, reduced the risk of drug interactions, and improved treatment safety.

CN118984820APending Publication Date: 2024-11-19SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033293.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-15
Filing Date
2023-04-14
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing estrogen receptor antagonists and degraders (SERD) compounds have suboptimal pharmacological properties when treating diseases such as breast cancer, especially CYP3A4 induction limitation, which leads to a high risk of drug-drug interactions.

Method used

Develop novel fluorinated N-propylpyrrolidine derivatives to reduce CYP3A4 induction, improve pharmacological properties, and reduce the risk of drug-drug interactions by selectively antagonizing and degrading estrogen receptors.

Benefits of technology

It achieves effective estrogen receptor inhibition and degradation in the treatment of diseases such as breast cancer, reduces CYP3A4 induction potential, reduces the risk of drug interactions, and improves treatment efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984820A_ABST
    Figure CN118984820A_ABST
Patent Text Reader

Abstract

Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 represent a hydrogen atom or a deuterium atom; r3 represents a hydrogen atom, a-COOH group or a-OH group; r3'and R3 ''represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; r4 and R5 represent a hydrogen atom, a halogen atom, a-NH2 group, a (C1-C3) alkyl group, a (C1-C3) alkoxy group, or a-OH group; or R4 and R5 together form an oxo group or R4 and R5 together form an = NOCH3 group or a (C3-C5) cycloalkyl group; r7 represents a hydrogen atom, a methyl group, an-OH group or a fluorine atom; r6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 4 to 7 membered heterocycloalkyl group, a (C1-C6) alkyl group or a phenyl (C1-C2) alkyl group; x represents-CH2-,-O-, or-S-; y represents-CH =,-N =, or-CR ''=; r8 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; r9 represents a hydrogen atom or a fluorine atom; r10 and R10'represent a hydrogen atom or a fluorine atom; r11 represents a hydrogen atom, a (C1-C3) alkyl group, or a cyclopropyl group; n is 0, 1 or 2, and m is 0 or 1. Further disclosed are processes for their preparation, pharmaceutical compositions comprising them and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Disclosed herein are novel fluorinated N-propyl-pyrrolidine derivatives, methods for their preparation, and their therapeutic uses, particularly as anticancer agents via selective antagonism and degradation of estrogen receptors.

[0002] Estrogen receptor (ER) belongs to the steroid / nuclear receptor superfamily involved in regulating eukaryotic gene expression, cell proliferation and target tissues. ER is in two forms: estrogen receptor α (ERα) and estrogen receptor β (ERβ) encoded by ESR1 and ESR2 genes, respectively. ERα and ERβ are ligand-activated transcription factors, which are activated by the hormone estrogen (the most potent estrogen produced in vivo is 17β-estradiol). In the absence of hormones, ER is mainly located in the cytosol of cells. When the hormone estrogen binds to ER, ER migrates from the cytosol of cells to the nucleus, forms a dimer, and then binds to a specific genomic sequence called an estrogen response element (ERE). DNA / ER complexes interact with co-regulators to regulate the transcription of target genes.

[0003] ERα is mainly expressed in reproductive tissues such as uterus, ovary, breast, bone and white adipose tissue. Abnormal ERα signaling leads to the development of a variety of diseases such as cancer, metabolic and cardiovascular diseases, neurodegenerative diseases, inflammatory diseases and osteoporosis.

[0004] ERα is expressed in no more than 10% of normal breast epithelium, but is expressed in approximately 50%-80% of breast tumors. Such breast tumors with high levels of ERα are classified as ERα-positive breast tumors. The etiological role of estrogen in breast cancer is established, and regulation of ERα signaling remains the mainstay of breast cancer treatment for most ERα-positive breast tumors. Currently, there are several strategies for inhibiting the estrogen axis in breast cancer, including: 1-blocking estrogen synthesis through aromatase inhibitors for the treatment of early and late ERα-positive breast cancer patients; 2-antagonizing estrogen ligand binding to ERα through tamoxifen for the treatment of ERα-positive breast cancer patients in both premenopausal and postmenopausal situations; 3-antagonizing and downregulating ERα levels through Fulvestrant for the treatment of breast cancer in patients who have progressed despite endocrine therapy such as tamoxifen or aromatase inhibitors.

[0005] Although these endocrine therapies have greatly contributed to the reduction of breast cancer development, about more than one-third of ERα-positive patients show resistance to such existing therapies from the beginning or develop resistance over time. Several mechanisms have been described to explain resistance to such hormone therapies. For example, the hypersensitivity of ERα to low estrogen levels in the treatment with aromatase inhibitors, the switching of tamoxifen effects from antagonists to agonist effects or multiple growth factor receptor signaling pathways in tamoxifen treatment. ERα acquired mutations that occur after the start of hormone therapy may also play a role in treatment failure and cancer progression. Certain mutations in ERα, particularly those identified in the ligand binding domain (LBD), lead to the ability to bind to DNA in the absence of a ligand and confer hormone independence in cells with such mutant receptors.

[0006] Most of the identified mechanisms of resistance to endocrine therapy rely on ERα-dependent activity. One of the new strategies to combat this resistance is to shut down ERα signaling by removing ERα from tumor cells using selective estrogen receptor degraders (SERDs). Clinical and preclinical data suggest that a number of resistance pathways can be circumvented by using SERDs.

[0007] There remains a need to provide SERDs with good degradation efficacy.

[0008] Documents WO2017 / 140669 and WO2018 / 091153 disclose some substituted 6,7-dihydro-5H-benzo[7]annulene compounds and substituted N-(3-fluoropropyl)-pyrrolidine derivatives that can be used as SERDs. However, as described in detail below, such compounds do not show optimized pharmacological profiles, especially with regard to the limitation of CYP3A4 induction.

[0009] The inventors have now discovered novel compounds capable of selectively antagonizing and degrading estrogen receptors (SERD compounds) for use in cancer treatment.

[0010] Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof:

[0011]

[0012] in

[0013] - R1 and R2 independently represent a hydrogen atom or a deuterium atom;

[0014] -R3 represents a hydrogen atom, a -COOH group or a -OH group;

[0015] - R3′ and R3″ independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group;

[0016] - R4 and R5 independently represent a hydrogen atom, a fluorine atom, a -NH2 group, a (C1-C3) alkyl group such as a methyl group, a (C1-C3) alkoxy group such as a methoxy group or an ethoxy group, or an -OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a =NOCH3 group or together with the carbon atom to which they are attached form a (C3-C5) cycloalkyl group;

[0017] -R7 represents a hydrogen atom, a methyl group, an -OH group or a fluorine atom;

[0018] or alternatively R4 and R7 together with the bonds to which they are attached form a cyclopropyl group which together with the adjacent pyrrolidine group yields an azaspiro[2.4]heptane;

[0019] -R6 represents a group selected from the following:

[0020] ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group;

[0021] ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl ring of which optionally contains unsaturation and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group and a (C1-C3)alkoxy group;

[0022] ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups;

[0023] ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6)alkyl group, a (C1-C6)fluoroalkyl group, a (C1-C6)alkoxy group, a (C1-C6)fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group;

[0024] ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0025] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0026] o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted with one or two halogen atoms or (C1-C3) alkyl;

[0027] ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group;

[0028] ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl or tetrahydrofuranyl, said heterocycloalkyl being saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups;

[0029] ■ (C1-C6) alkyl, such as isobutyl or ethylbutyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and

[0030] ■phenyl (C1-C2) alkyl, the phenyl group being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: a halogen atom; a (C1-C3) alkyl group; a (C1-C3) fluoroalkyl group; a (C1-C3) alkoxy group; a (C1-C3) fluoroalkoxy group; a cyano group; and an -OH group;

[0031] -X represents -CH2-, -O-, or -S-;

[0032] -Y represents -CH=, -N= or -CR"=, wherein R" represents a (C1-C3)alkyl group or a halogen atom such as a fluorine or chlorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group;

[0033] - R8 independently represents a (C1-C3) alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3) fluoroalkyl group such as a trifluoromethyl group;

[0034] -R9 represents a hydrogen atom or a fluorine atom;

[0035] - R10 and R10' independently represent a hydrogen atom or a fluorine atom;

[0036] -R11 represents a hydrogen atom, or a (C1-C3) alkyl group or a cyclopropyl group;

[0037] -n is 0, 1, or 2, and

[0038] -m is 0 or 1.

[0039] The compounds of formula (I) may contain one or more asymmetric carbon atoms and may therefore exist in the form of enantiomers.

[0040] The compounds of formula (I) may also exist in tautomeric forms.

[0041] The compound of formula (I) may exist in the form of a base, an acid, a zwitterion or an addition salt with an acid or a base. Accordingly, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0042] These salts may be prepared with pharmaceutically acceptable acids or bases, although salts of other acids or bases useful, for example, in the purification or isolation of compounds of formula (I) are also provided.

[0043] Among suitable salts of the compounds of formula (I), hydrochlorides may be cited.

[0044] As used herein, unless otherwise noted, the following terms have the following definitions throughout this specification:

[0045] - halogen atoms: fluorine, chlorine, bromine or iodine atoms, and in particular fluorine and chlorine atoms;

[0046] -Oxo: "=O" group;

[0047] - Alkyl: a straight or branched saturated hydrocarbon aliphatic group, which, unless otherwise specified, contains from 1 to 6 carbon atoms (indicated as "(C1-C6) alkyl"). By way of example, but not limited to: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl and isohexyl, etc. may be mentioned;

[0048] - Cycloalkyl: saturated or partially unsaturated and unsubstituted or substituted monocyclic alkyl radicals, which, unless otherwise indicated, contain from 3 to 7 carbon atoms. By way of example, but not limited to, mention may be made of: cyclopropyl, cyclobutyl, cyclopentyl, cyclobutenyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, etc., in particular cyclopentyl, cyclohexyl, cycloheptyl, cycloheptenyl or cyclohexenyl;

[0049] - Cycloalkylalkyl: alkyl substituted by a cyclic alkyl as defined above. Mention may be made, but is not limited to: cyclobutylmethyl;

[0050] - Heterocycloalkyl: saturated or partially unsaturated 4 to 7 membered cycloalkyl containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, in particular oxygen or nitrogen. By way of example, but not limited to, mention may be made of: morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, aziridinyl, oxanyl, oxetanyl, tetrahydropyranyl, morpholinyl, tetrahydrofuranyl, oxepanyl, diazepanyl, dioxanyl, tetrahydropyranyl and tetrahydrothiopyranyl. Heterocycloalkyl is advantageously tetrahydrofuranyl or tetrahydropyranyl.

[0051] -Fluoroalkyl: an alkyl group as defined previously, wherein the alkyl group is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl group is replaced by a fluorine atom. By way of example, -CH2F, -CHF2, -CH2CHF2, -CH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl group are replaced by fluorine atoms, the fluoroalkyl group may be named as a perfluoroalkyl group. By way of example, trifluoromethyl or trifluoroethyl, etc. may be mentioned;

[0052] -Alkoxy: -O-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methoxy; ethoxy; propoxy; isopropoxy; linear butoxy, sec-butoxy or tert-butoxy; isobutoxy; pentyloxy or hexyloxy, etc.;

[0053] -Fluoroalkoxy: -O-alkyl, wherein alkyl is as defined previously and wherein alkyl is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl is replaced by a fluorine atom. By way of example, -OCH2F, -OCHF2, -OCH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl are replaced by fluorine atoms, the fluoroalkoxy may be named as perfluoroalkoxy. By way of example, trifluoromethoxy, etc. may be mentioned;

[0054] -(C1-C4)alkylthio, which is also named (C1-C4)alkylsulfanyl: -S-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methylthio, ethylthio, propylthio, isopropylthio, straight-chain secondary or tert-butylthio, isobutylthio, etc.;

[0055] -(C1-C4)alkylsulfonyl: -SO2-alkyl, wherein alkyl is as defined above. For example, -SO2CH3, -SO2CH2CH3, etc. may be mentioned but are not limited thereto;

[0056] -(C1-C4)fluoroalkylthio, which is also named (C1-C4)fluoroalkylsulfanyl: -S-fluoroalkyl, wherein the fluoroalkyl group is as defined above. For example, there can be mentioned but are not limited to: fluoromethylthio, difluoromethylthio, trifluoromethylthio, etc.;

[0057] - Fused phenyl: a bicyclic radical comprising from 7 to 10 carbon atoms and containing a phenyl moiety. The phenyl moiety may be fused to a (C3-C6)cycloalkyl group, i.e. the phenyl moiety may share a bond with the (C3-C6)cycloalkyl group. The fused phenyl group may be bound to the rest of the molecule via its phenyl moiety. It may be substituted. Examples are, but are not limited to, indanyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, tetrahydronaphthyl, etc.;

[0058] -Heteroaryl: A cyclic 5- to 10-membered aromatic group containing 2 to 9 carbon atoms and 1 to 3 heteroatoms such as nitrogen, oxygen or sulfur. Such nitrogen atoms may be replaced by oxygen atoms to form -NO bonds. Such -NO bonds may be in the form of N-oxides (-N + -O - ) in the form of. The heteroaryl group may be monocyclic or bicyclic. As examples of heteroaryl groups, mention may be made, but is not limited to: thiophene, furan, thiadiazole, thiazole, imidazole, pyridazine, triazine, pyrazine, oxadiazole, pyrazole, isothiazole, oxazole, isoxazole, pyridine, pyrimidine, benzotriazole, benzoxazole, pyrrolo[2,3-b]pyridine, benzimidazole, benzooxadiazole, benzothiazole, benzothiadiazole, benzofuran, indole, isoquinoline, indazole, benzisoxazole, benzisothiazole, pyridone groups and the like. Heteroaryl groups are advantageously pyridine, pyrrole, imidazole, pyrazine, furan, thiazole, pyrazole, thiadiazole, pyridazine, pyridone and pyrimidine, and more particularly pyridine, pyridone and pyrrole;

[0059] - Bicyclic radicals generally containing from 5 to 12 carbon atoms are hydrocarbon radicals chosen from radicals containing two rings connected by:

[0060] ● Single common atom: "spiro bicyclic". Such spiro bicyclic alkyl groups usually contain 5 to 11 carbon atoms and refer to "spiro (C5-C 11 The ring may be saturated or partially unsaturated. Such spiro bicyclic rings may be unsubstituted or substituted, in particular substituted by at least one (C1-C3)alkyl group such as methyl or fluorine. Regarding the definition of R6, as spiro (C5-C 11 ) Examples of bicyclic rings include, but are not limited to, spiro[2.3]hexane, spiro[3.3]heptane, spiro[3.3]heptene, spiro[2.5]octane and 7-azaspiro[3.5]nonane. Also for the R6 group, spiro(C5-C 11 ) The bicyclic ring is advantageously spiro[3.3]heptane or spiro[3.3]heptene.

[0061] ● Two common atoms: in this case, the bicyclic radical contains 7 to 12 carbon atoms and optionally contains 1 to 2 degrees of unsaturation. As examples of such bicyclic radicals, mention may be made, without limitation, of cis-1,3a,4,5,6,6a-hexahydrocyclopentadienyl, bicyclo[3.1.0]hex-1-yl and bicyclo[4.1.0]heptanyl.

[0062] ● Three or more common atoms: In this case, the bicyclic group contains 6 to 10 carbon atoms and such a bicyclic group may be referred to as a "bridged (C6-C 10 )cycloalkyl", the ring has three or more atoms in total and the bridge contains at least one atom, such as 1, 2 or 3 atoms and preferably 1 atom. As examples of such bridged cycloalkyl groups, mention may be made, but are not limited to, bicyclo[3.2.1]octan-3-yl and bicyclo[2.2.1]hept-2-yl.

[0063] - Zwitterion means: a generally neutral molecule having both positive and negative charges and possessing both acidic and basic groups.

[0064] In another embodiment, in the compounds of formula (I) as defined above, R1 and R2 are hydrogen atoms.

[0065] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group or a -OH group, more particularly R3 is a -COOH group.

[0066] In another embodiment, in the compounds of formula (I) as defined above, when m is 1, X represents -CH2- or -O-.

[0067] In another embodiment, in the compounds of formula (I) as defined above, X represents -CH2- or -O-, in particular X represents -CH2-.

[0068] In another embodiment, in the compound of formula (I) as defined above, R4 and R5 independently represent a hydrogen atom or a fluorine atom, more particularly R4 and R5 both represent a hydrogen atom or R4 and R5 both represent a fluorine atom.

[0069] In another embodiment, in the compounds of formula (I) as defined above, R4 and R5 both represent a hydrogen atom.

[0070] In another embodiment, in the compounds of formula (I) as defined above, R7 represents a hydrogen atom or a fluorine atom, more particularly a hydrogen atom.

[0071] In another embodiment, in the compound of formula (I) as defined above:

[0072] - R4 and R5 independently represent a hydrogen atom, a -NH2 group, a (C1-C3) alkyl group such as a methyl group, a (C1-C3) alkoxy group such as a methoxy group or an ethoxy group, or an -OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a =NOCH3 group or together with the carbon atom to which they are attached form a (C3-C5) cycloalkyl group, and

[0073] -R7 represents a hydrogen atom, a methyl group or an -OH group;

[0074] Or alternatively R4 and R7 together with the bonds to which they are attached form a cyclopropyl group which together with the adjacent pyrrolidine group yields an azaspiro[2.4]heptane.

[0075] In another embodiment, in the compound of formula (I) as defined above, R6 represents a group selected from:

[0076] -phenyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group;

[0077] - a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6) alkyl group, a (C1-C6) fluoroalkyl group, a (C1-C6) alkoxy group, a (C1-C6) fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group; and

[0078] - a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C3) alkyl group, a (C1-C3) fluoroalkyl group, a (C3-C6) cycloalkyl group, a (C1-C3) alkoxy group, a (C1-C3) fluoroalkoxy group, an oxo group and a phenyl group optionally substituted by a halogen atom or a (C1-C3) alkyl group.

[0079] In another embodiment, in the compound of formula (I) as defined above, R6 represents a phenyl group, which is optionally substituted by 1 to 3 substituents independently selected from: a halogen atom, a (C1-C6) alkyl group and a (C1-C6) fluoroalkyl group; more particularly selected from: a fluorine atom, a chlorine atom, a methyl group and a trifluoromethyl group. In such an embodiment, in particular, at least one of the substituents of the phenyl group comprises a halogen atom.

[0080] In another embodiment, in the compounds of formula (I) as defined above, R6 represents pyridinyl optionally substituted with 1 to 3 substituents independently selected from (C1-C6)alkoxy, more particularly methoxy.

[0081] In another embodiment, in the compounds of formula (I) as defined above, R6 represents a saturated or partially saturated cyclohexyl, more particularly a cyclohexyl or cyclohexenyl, said saturated or partially saturated cyclohexyl being optionally substituted by 1 to 4 substituents independently selected from (C1-C3)alkyl, more particularly by 1 to 4 methyl groups.

[0082] In another embodiment, in the compounds of formula (I) as defined above, R3′ and R3″ both represent a hydrogen atom.

[0083] In another embodiment, in the compounds of formula (I) as defined above, n is 0.

[0084] In another embodiment, in the compounds of formula (I) as defined above, Y represents -CH=.

[0085] In another embodiment, in the compounds of formula (I) as defined above, R9 represents a hydrogen atom.

[0086] In another embodiment, in the compound of formula (I) as defined above, R10 and R10′ both represent a hydrogen atom; or one of R10 and R10′ represents a hydrogen atom and the other represents a fluorine atom.

[0087] In another embodiment, in the compounds of formula (I) as defined above, R10 and R10' both represent a hydrogen atom.

[0088] In another embodiment, in the compounds of formula (I) as defined above, R11 represents a hydrogen atom or a methyl group, more particularly a hydrogen atom.

[0089] In another embodiment, in the compounds of formula (I) as defined above, m is 1.

[0090] In another embodiment, in the compound of formula (I) as defined above, R3 is a -COOH group and R6 is a phenyl group comprising one, two or three substituents independently selected from chlorine atoms, fluorine atoms, chlorine atoms, methyl and trifluoromethyl, at least one of the substituents comprising a halogen atom. In such an embodiment, R3' and R3" are in particular hydrogen atoms. In such an embodiment, R1, R2, R4, R5, R7, R9 and R11 are hydrogen atoms. In such an embodiment, R10 and R10' are both hydrogen atoms or one of R10 and R10' is a hydrogen atom and the other is a fluorine atom. In such an embodiment, Y is -CH=, m is equal to 1 and n is equal to 0. In such an embodiment, X is a -CH2- group.

[0091] Among the compounds of formula (I) described herein, the following compounds or their pharmaceutically acceptable salts, in particular their hydrochlorides, may be mentioned in particular:

[0092] -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (S) isomer (1),

[0093] -8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(2),

[0094] -8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(3),

[0095] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(4),

[0096] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(5),

[0097] -8-(3-chloro-2-methylphenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(6),

[0098] -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Carboxylic acid hydrochloride, isomer 1(7),

[0099] -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Carboxylic acid hydrochloride, isomer 2(8),

[0100] -8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(9),

[0101] -8-(2,4-difluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(10),

[0102] -8-(4,4-dimethylcyclohex-1-en-1-yl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(11),

[0103] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(12),

[0104] -8-(3-chloro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(13),

[0105] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(6-methoxypyridin-3-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(14),

[0106] -8-(3-chloro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(15),

[0107] -8-(3-chloro-2-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(16),

[0108] -8-(4-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(17),

[0109] -8-(4-fluoro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(18),

[0110] -8-(2,4-difluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(19),

[0111] -8-(3-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(20),

[0112] -8-(2-chloro-3-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(21),

[0113] -8-(2,4-dichlorophenyl)-9-(4-((3-fluoro-1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, 2,2,2-trifluoroacetic acid, isomer 2 (22),

[0114] -8-(2,4-dichlorophenyl)-9-(4-((3-fluoro-1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, 2,2,2-trifluoroacetic acid, isomer 1 (23),

[0115] -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (R) isomer (24),

[0116] -3-(2,4-dichlorophenyl)-4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylic acid hydrochloride, isomer 1(25),

[0117] -8-(2,4-dichlorophenyl)-9-(4-(difluoro(1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(26),

[0118] -8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(27),

[0119] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1 (28),

[0120] -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride, isomer 1(29),

[0121] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(30),

[0122] -8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride, isomer 1(31),

[0123] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2,6-dimethylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(32),

[0124] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (33),

[0125] -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(34),

[0126] -8-(4-fluoro-2,6-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(35),

[0127] -6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, isomer 1 (36),

[0128] -8-(4-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(37),

[0129] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1 (38),

[0130] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(39),

[0131] -8-(3-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(40),

[0132] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(41),

[0133] -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2 (42),

[0134] -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1 (43),

[0135] -4-(2-chlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1 (44).

[0136] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in therapy, especially as an inhibitor and degrader of estrogen receptors.

[0137] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, especially breast cancer.

[0138] Another embodiment is a method of inhibiting and degrading estrogen receptors, which comprises administering a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof to a subject, especially a human, in need thereof.

[0139] Another embodiment is a method for treating ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0140] Another embodiment is a method of treating cancer, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0141] Another embodiment is a pharmaceutical composition comprising, as an active ingredient, an effective dose of a compound selected from the above list or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0142] The inventors unexpectedly emphasized that the compounds of formula (I) exhibit improved pharmacological properties by minimizing CYP3A4 induction, in particular as CYP3A4 non-inducers, which was not predictable from the prior art, in particular in view of WO2017 / 140669 and WO2018 / 091153. The following explanatory section emphasizes this unexpected property compared to chemical compounds representing the prior art and in relation to a large number of compounds of formula (I) of the present invention.

[0143] Cytochrome P450 isoform 3A4 (CYP3A4) is involved in the metabolism of approximately 30% of clinically used drugs in almost all therapeutic classes. Therefore, the evaluation of CYP3A4 induction potential is important for the prediction of drug-drug interactions due to CYP3A4 overexpression. More precisely, low CYP3A4 induction indicates limited undesired drug-drug interactions. In particular, the measurement of a compound's CYP3A4 induction potential is part of its overall ADME (absorption, distribution, metabolism, excretion) evaluation.

[0144] Therefore, another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in therapy, especially as an inhibitor and degrader of estrogen receptors, which at the same time exhibits improved pharmacological properties, especially showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0145] As used herein, with respect to a compound, the term "no CYP3A4 induction, or weak or moderate CYP3A4 induction" does not relate to the extent of CYP3A4 induction, or does not relate to a weak or moderate extent of CYP3A4 induction, respectively, which is typically calculated from the results of the test "CYP3A4 induction potential for evaluation of ADME properties" compared to the reference compound rifampicin and designated as "% E max ". For example, such a test is based on the quantification of CYP3A4 mRNA induction by RT-PCR analysis. The %E max It can be calculated as detailed in the description section according to the following formula:

[0146]

[0147] E 化合物 : Relative fold mRNA expression after treatment with test compounds,

[0148] E 阳性对照 : Relative fold mRNA expression after reference inducer (i.e., 10 μM rifampicin),

[0149] E 媒介物对照 : Relative fold mRNA expression after vehicle treatment (ie, 0.1% DMSO), and

[0150] E is the efficiency of quantitative PCR.

[0151] Typically, its E max Compounds with an E of 20% or less can be considered as compounds showing weak or no CYP3A4 induction (low risk of drug-drug interaction) and their E maxCompounds accounting for 20% to 45% can be considered as compounds showing moderate CYP3A4 induction (limited risk of drug-drug interactions).

[0152] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, especially breast cancer, which at the same time shows improved pharmacological properties, typically low or limited risk of drug-drug interactions, especially showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0153] Another embodiment is a method of inhibiting and degrading estrogen receptors, which comprises administering to a subject in need thereof, particularly a human, a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof, which exhibits improved pharmacological properties, typically low or limited risk of drug-drug interactions, and particularly shows no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0154] Another embodiment is a method for treating ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation, comprising administering to a subject in need thereof, particularly a human, a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof, which exhibits improved pharmacological properties, typically low or limited risk of drug-drug interactions, particularly showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0155] Another embodiment is a method of treating cancer, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof, which exhibits improved pharmacological properties, typically low or limited risk of drug-drug interactions, particularly showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0156] The compound of formula (I) can be prepared by the following method.

[0157] Compounds of formula (I) and other related compounds with different substituents are synthesized using techniques and materials described below or otherwise known to those skilled in the art. In addition, the solvents, temperatures and other reaction conditions presented below may be varied as deemed appropriate by those skilled in the art.

[0158] The following general methods for preparing compounds of formula (I) optionally modified by use of appropriate reagents and conditions for introducing the various moieties found in formula (I) are described below.

[0159] The following abbreviations and empirical formulas are used:

[0160] ADME absorption, distribution, metabolism and excretion

[0161] AIBN Azobisisobutyronitrile

[0162] MeCN Acetonitrile

[0163] NH4Cl Ammonium chloride

[0164] CO Carbon monoxide

[0165] DDI Drug-Drug Interactions

[0166] BAST Deoxo-Fluor

[0167] Cs2CO3 Cesium carbonate

[0168] CYP3A4 Cytochrome P450 (CYP) 3A4

[0169] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0170] DCM Dichloromethane

[0171] Et2O Ether

[0172] DIEA Diisopropylethylamine

[0173] DMF N,N-Dimethylformamide

[0174] DMAP dimethylaminopyridine

[0175] DMSO Dimethyl sulfoxide

[0176] Boc2O Di-tert-butyl dicarbonate

[0177] EtOH

[0178] EtOAc Ethyl acetate

[0179] H2 Hydrogen

[0180] HCl

[0181] IsoPrOH Isopropyl alcohol

[0182] LiHMDS Lithium bis(trimethylsilyl)amide

[0183] LiOH Lithium Hydroxide

[0184] MeOH Methanol

[0185] MgSO4 Magnesium sulfate

[0186] MeTHF 2-Methyltetrahydrofuran

[0187] Pd / C Palladium / Carbon

[0188] KOAc Potassium acetate

[0189] KHMDS Potassium bis(trimethylsilyl)amide

[0190] K2CO3 Potassium carbonate

[0191] NaBH4 Sodium borohydride

[0192] NaHCO3 Sodium bicarbonate

[0193] NaH Sodium hydride

[0194] NaOH Sodium hydroxide

[0195] Na2SO4 Sodium sulfate

[0196] NaHSO3 Sodium bisulfate

[0197] SCX Strong Cation Exchange

[0198] PCR polymerase chain reaction

[0199] Pd(dppf)Cl2 [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride

[0200] Pd(PPh3)2Cl2 Bis(triphenylphosphine)palladium(II) dichloride

[0201] Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)

[0202] PhOK Potassium Phenolate

[0203] SFC Supercritical Fluid Chromatography

[0204] TEA Triethylamine

[0205] TFA Trifluoroacetic acid

[0206] THF Tetrahydrofuran

[0207] PPh3 Triphenylphosphine

[0208] RT Room temperature

[0209] RT-PCR Reverse transcriptase PCR

[0210] Option 1a Parts 1 and 2 : Preparation of compounds of formula (I) - General method

[0211] Option 1a – Part 1 :

[0212]

[0213] Option 1a – Part 2 :

[0214]

[0215] According to Scheme 1a - Part-1 and Part-2, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, and R1, R2, R3, R3', R3", R4, R5, R6, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined above, compound 1A (when X=C, prepared according to WO 2017140669) can be converted to compound 1C in step 1 by treating with compound 1B in the presence of a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in a solution in toluene by heating to solvent reflux in the presence of a base such as KOPh.

[0216] Compound 1C can be converted to compound 1E in step 2 by treating with compound 1D using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux in a Suzuki coupling reaction.

[0217] Alternatively, compound 1E can be obtained in step 1′ by Suzuki coupling between compound 1A and compound 1D′ using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0218] Compound IE can be converted to compound IF in step 3 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0219] This bromo derivative intermediate 1F can then be subjected in step 4 to a second Suzuki coupling with a suitable boronic acid reagent R6B(OR')2 (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above) using, for example, Pd(dppf)Cl2 complexed with DCM as a catalyst, in a mixture of dioxane and water as solvent and in the presence of a base (e.g. Cs2CO3) at room temperature or by heating to reflux to give compound 1G. When R6 is a substituted cycloolefin, heterocycloolefin or aliphatic ethylene, it can be reduced by, for example, hydrogenation with a catalyst such as Pd / C at a temperature up to 70°C under a hydrogen pressure (H2) of about 5 bar to give the corresponding saturated compound 1G.

[0220] Alternatively, compound 1F can be subjected to a photocatalytic coupling reaction with R6Br (wherein R6 is alkyl, cycloalkyl or spirobicycloalkyl as defined above) using a catalyst such as (Ir[dF(CF3)ppy]2(dtbpy))PF6 and nickel(II) chloride ethylene glycol dimethyl ether complex in the presence of tris(trimethylsilyl)silane and a base such as 4,4'-di-tert-butyl-2,2'-bipyridine and sodium carbonate to give the corresponding compound 1G.

[0221] Compound 1G can be converted to a compound of formula (I) in step 5 in the presence of a hydroxide ion source such as NaOH in solution in methanol (MeOH).

[0222] Compound 1F can be converted to compound 1Fa in step 6 in the presence of a hydroxide ion source such as NaOH in solution in methanol (MeOH).

[0223] The compound 1Fa can be converted to compound I in step 7 by Suzuki conditions using a suitable boronic acid reagent R6B(OR')2 (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above), using, for example, Pd(dppf)Cl2 complexed with DCM as a catalyst, in a mixture of dioxane and water as solvent and in the presence of a base (e.g. Cs2CO3), at room temperature or by heating to reflux of the solvent. When R6 is a substituted cycloolefin, heterocycloolefin or aliphatic ethylene, it can be reduced by, for example, hydrogenation with a catalyst such as Pd / C at a temperature of up to 70°C under a hydrogen (H2) pressure of about 5 bar to give the corresponding saturated compound I.

[0224] When R3a is COOMe, COOEt or a protected OH such as O-pivaloyl, deprotection can be carried out in step 5 by treatment with an aqueous solution of sodium hydroxide (NaOH) 2N or lithium hydroxide (LiOH) in MeOH. When R3 is COOH, extraction of the product can give the sodium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can give the neutral form of compound I. Acidification with an aqueous solution of HCl 2N to pH 1-2 can give the hydrochloride salt of compound I. Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can give the formate or trifluoroacetate salt of compound I.

[0225] Option 1b : Alternative preparation of compounds of formula (1E)

[0226]

[0227] According to Scheme 1b, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or OH protected, for example, with an O-pivaloyl group, and R1, R2, R3, R3′, R3″, R4, R5, R7, R8, R9, R10, R10′, R11, n, m, X and Y are as defined above, compound 1E′ can be prepared in a Suzuki coupling reaction between compound 1C and 1Da in step 1 or between compound 1A and 1Da′ in step 1′ in the presence of a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating until the solvent refluxes.

[0228] Compound 1E' can be converted to compound 1E in step 2 in the presence of TFA followed by treatment with compound 1Ea (where W is Cl, Br or I or OS2R where R=CH3, PhMe, CF3 or CF2CF2CF2CF3) in the presence of a base such as potassium carbonate in DMF as solvent.

[0229] Solution 1c : Preparation of compounds of formula (I) - General method

[0230]

[0231] According to Scheme 1c, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl, R11 is a hydrogen atom and R1, R2, R3, R3', R3", R4, R5, R6, R7, R8, R9, R10, R10', n, m, X and Y are as defined above, compound 1F can be converted to compound 1H in step 1 by, for example, treating with compound 1B and using a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene by heating to solvent reflux in the presence of a base such as KOPh.

[0232] Compound 1G (wherein R6 is phenyl or heteroaryl) can be prepared in step 2 in a Suzuki coupling reaction between compound 1H and R6Br or R6I or R6OTf using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0233] When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, compound 1G can be converted to a compound of formula (I) in step 3 in the presence of a hydroxide ion source such as NaOH in solution in methanol (MeOH). When R3 represents a -COOH group, extraction of the product can afford the sodium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can afford the neutral form of compound I. Acidification with an aqueous solution of HCl 2N to pH 1-2 can afford the hydrochloride salt of compound I. Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can afford the formate or trifluoroacetate salt of compound I.

[0234] Scheme 1d – Part-1 : Preparation of compounds of formula (I) - General method

[0235]

[0236] Scheme 1d – Part 2

[0237]

[0238] According to Scheme 1d - Part-1 and Part-2, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or a protected OH such as O-pivaloyl, R11 is a hydrogen atom, R6 is a phenyl or heteroaryl group, and R1, R2, R3, R3', R3", R4, R5, R7, R8, R9, R10, R10', n, m, X and Y are as defined above, compound 1I can be converted to compound 1J in step 1 by treatment with an aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst such as tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution in toluene or xylene by heating to solvent reflux in the presence of a base such as K2CO3 or Cs2CO3. An alternative way to prepare compound 1J (wherein R6 can be any group as defined above for R6 in formula (I)) is described in Scheme 1g below.

[0239] Compound 1J can be converted to compound 1K in step 2 by treatment with N,N-bis(trifluoromethylsulfonyl)aniline in the presence of a base such as DBU or NaH or KHMDS in a solvent such as MeTHF at -50 °C.

[0240] Compound 1K can be converted to compound 1L in step 3 by, for example, treating compound 1B with a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene in a solution by heating to solvent reflux in the presence of a base such as KOPh.

[0241] Compound 1G can be prepared in step 4 in a Suzuki coupling reaction between compounds 1L and 1D using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0242] Alternatively, compound 1L can be converted to compound 1N in step 6 in a Suzuki coupling reaction with compound 1M using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0243] Compound 1N can be reduced to compound 1O in step 7 by hydrogenation with a catalyst such as PtO 2 at a hydrogen (H 2 ) pressure of about 2 bar, for example at room temperature.

[0244] When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, compound 1G or 1O can be converted to a compound of formula (I) in step 5 or step 8 in the presence of a hydroxide ion source such as NaOH in a solution in methanol (MeOH). When R3 represents a -COOH group, extraction of the product can give the sodium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can give the neutral form of compound I. Acidification with an aqueous solution of HCl 2N to pH 1-2 can give the hydrochloride salt of compound I. Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can give the formate or trifluoroacetate salt of compound I.

[0245] Option 1e : Preparation of compounds of formula (I) - General method

[0246]

[0247] According to Scheme 1e, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or a protected OH such as O-pivaloyl, and R1, R2, R3, R3′, R3″, R4, R5, R6, R7, R8, R9, R10, R10′, R11, n, m, X and Y are as defined above, compound 1K can be converted to compound 1G in step 1 by treatment with compound 1D′ in the presence of a palladium catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM) in a mixture of dioxane and water and in the presence of a base (e.g., cesium carbonate (Cs2CO3)) by heating until the solvent refluxes.

[0248] When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, compound 1G can be converted to a compound of formula (I) in step 2 in the presence of a hydroxide ion source such as NaOH in solution in methanol (MeOH). When R3 represents a -COOH group, extraction of the product can afford the sodium salt of compound I. Acidification with an aqueous solution of HCl 2N to pH 6-7 can afford the neutral form of compound I. Acidification with an aqueous solution of HCl 2N to pH 1-2 can afford the hydrochloride salt of compound I. Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can afford the formate or trifluoroacetate salt of compound I.

[0249] Scheme 1f : Preparation of compounds of formula (1A) (wherein R3a = CO2Me) - General method

[0250]

[0251] According to Scheme 1f, wherein X, m, R3', R3" and R11 are as defined above, compound 1A may be commercially available or prepared as follows: Compound 1P (commercially available or prepared according to WO 2017140669 and WO 2018091153) may be converted to compound 1Q in step 1 by treatment with trifluoromethanesulfonic anhydride in a solution in DCM in the presence of pyridine as base.

[0252] Compound 1Q can be converted to compound 1I' in step 2 by carbonylation with carbon monoxide in the presence of a palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM in a solution in DMF and MeOH.

[0253] Compound 1I' can be converted in step 3 to compound 1A, wherein R3a = CO2Me, by treatment with trifluoromethanesulfonic anhydride in solution in DCM in the presence of pyridine as base.

[0254] Solution 1g : Alternative preparation of compounds of formula (1J) - General method

[0255]

[0256] According to Scheme 1g, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or OH protected, for example, with an O-pivaloyl group, and R3′, R3″, R6, R11, X and m are as defined above, compound 1J can alternatively be prepared as follows: Compound 1I can be converted to compound 1R in step 1 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0257] Compound 1R can be converted to compound 1S in step 2 by deprotonation with a base such as LiHMDS in THF followed by treatment with acetic anhydride.

[0258] Compound 1T can be prepared in step 3 in a Suzuki coupling reaction between compound 1S and R6B(OR')2 or R6BF3K (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above) using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of toluene and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0259] Compound 1T can be converted to compound 1J in step 4, for example, by hydrolysis with aqueous HCl by heating in methanol and DCM.

[0260] Also provided herein is a process for preparing a compound of formula (I) as defined above, wherein the compound of formula 1G

[0261]

[0262] - wherein R1, R2, R3', R3", R4, R5, R6, R7, R8, R9, R10, R10', R11, n, m, X and Y are defined above, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl - is converted to a compound of formula (I) in solution in methanol in the presence of a hydroxide ion source such as NaOH, said step optionally being preceded by a step to obtain compound 1G, wherein a compound of formula 1F ...

[0263]

[0264] - wherein R1, R2, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined above and R3a is as defined above - subjected to Suzuki coupling with a boronic acid reagent R6-B(OR')2 (wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is as defined above).

[0265] Also provided herein is a process for preparing a compound of formula (I) as defined above, wherein a compound of formula 1Fa

[0266]

[0267] - wherein R1, R2, R3, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined above - subjected to Suzuki coupling of boronic acid reagent R6-B(OR')2 (wherein -B(OR')2 is boronic acid or pinacol ester and R6 is as defined above), said step optionally being preceded by a step for obtaining compound 1Fa, wherein a compound of formula 1F

[0268]

[0269] -- wherein R1, R2, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined above and R3a is as defined above -- is converted to compound 1Fa in solution in methanol in the presence of a hydroxide ion source such as NaOH.

[0270] Also provided herein is an intermediate compound selected from the compounds of Formula 1E, 1F, 1G and 1Fa or any pharmaceutically acceptable salt thereof,

[0271]

[0272] wherein R1, R2, R3, R3′, R3″, R4, R5, R6, R7, R8, R9, R10, R10′, R11, n, m, X and Y are as defined above, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or a protected OH such as O-pivaloyl.

[0273] Further provided herein are intermediate compounds of Formula 1D and 1D' or any pharmaceutically acceptable salt thereof

[0274]

[0275] wherein R1, R2, R4, R5, R7, R8, R9, R10, R10′, n and Y are as defined above.

[0276] In another aspect, there is also provided herein a process for preparing a compound of formula (I) wherein R3 is a -COOH group, comprising a deprotection step of a compound of formula 1G as defined above, optionally followed by a purification step.

[0277] The purification step may, for example, consist of an acidification step (eg with aqueous hydrochloric acid) as shown in step 2 of Example 1 hereinafter.

[0278] Further provided herein are intermediate compounds of Formula 1L or any pharmaceutically acceptable salt thereof

[0279]

[0280] wherein R3a, R3′, R3″, X, m and R6 are as defined above and R11 is a hydrogen atom.

[0281] At 400 and 500MHz 1 H NMR spectra were performed on Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometers, respectively, with chemical shifts (δ, in ppm) in the solvent dimethyl sulfoxide-d6 (d6-DMSO) referenced to 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in Hertz.

[0282] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a UPLC Acquity Waters instrument using UV detection DAD 210-400 nm and fast Acquity UPLC CSH C18 1.7 μm, size 2.1x30 mm, mobile phase H2O+0.1% HCO2H / CH3CN+0.1% HCO2H, light scattering detector Sedere and SQD Waters mass spectrometer.

[0283] Tables 1a and 1b below contain specific compounds (names and structures) of formula (I) according to the present disclosure and their characterizations ( 1 H NMR and LC / MS / MS).

[0284] Table 1a:

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295] Table 1b :

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311] The following examples describe the preparation of some of the compounds of formula (I) described herein. The quantities of the compounds exemplified below match those given in Table 1 above. Unless otherwise specified, all reactions were performed under an inert atmosphere.

[0312] In the following examples, when the origin of the starting product is not specified, it is understood that the product is a known compound.

[0313] Intermediates:

[0314] Intermediate 1: 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine, isomer 1 and isomer 2

[0315]

[0316] Step 1: tert-Butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate, Isomer 1 and Isomer 2

[0317]

[0318] At room temperature, DMAP (1.78g, 14.57mmol) and Boc are added to the solution of commercially available 3-(4-bromobenzyl) pyrrolidine (35.0g, 145mmol) and TEA (29.5g, 292mmol) in DCM (250ml) o (33.4g, 153mmol), and the suspension is stirred at room temperature for 12 hours. By adding water (300ml), the reaction mixture is quenched and extracted with DCM (100ml). Organic phase is washed with saline (200ml), through Na sO dried, filtered and concentrated under reduced pressure, and the obtained residue is purified by flash chromatography with the gradient elution of petroleum ether / ethyl acetate from 98 / 02 to 50 / 50 to obtain 37g (73%) of 3-(4-bromobenzyl) pyrrolidine-1-tert-butyl formate in light yellow oil.

[0319] A mixture of isomers of tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate (37 g, 107 mmol) was separated by preparative SFC (column: DAICEL CHIRALCEL OJ (250 x 50 mm, 10 μm); supercritical CO2 80% / [0.1% NH4OHEtOH] 20%) to give 17 g of tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate isomer 1 and 17 g of tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate isomer 2.

[0320] LC / MS(m / z,MH+):340

[0321] Step 2: 3-(4-bromobenzyl)pyrrolidine hydrochloride, isomer 1

[0322]

[0323] To a solution of tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate isomer 1 (17.0 g, 50.0 mmol) in EtOAc (160 ml) was added a 4N solution of HCl in dioxane (50 ml, 200 mmol), and the mixture was stirred at room temperature for 2 hours. The solution was concentrated under vacuum to give 17 g (crude) of compound 3-(4-bromobenzyl)pyrrolidine hydrochloride, isomer 1.

[0324] LC / MS(m / z,MH+):240

[0325] Step 3: 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine, Isomer 1

[0326]

[0327] To 3-(4-bromobenzyl)pyrrolidine hydrochloride, isomer 1 (12g, 43.4mmol) and KCO in a mixture of DMF (84ml) 1-fluoro-3-iodo-propane (8.56g, 45.55mmol) was added, and the mixture was heated to 80°C for 2 hours. The reaction mixture was quenched by adding water (400ml) and extracted twice with EtOAc (200ml). The combined organic phases were washed with brine (200ml), dried over NaSO, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of DCM / MeOH from 100 / 00 to 90 / 10 to obtain 10g (76%) of 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine, isomer 1.

[0328] LC / MS(m / z,MH+):300

[0329] Step 2': 3-(4-bromobenzyl)pyrrolidine hydrochloride, isomer 2

[0330]

[0331] Intermediate 1 Isomer 2, Step 2' was prepared from tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate Isomer 2 following a procedure similar to that of Intermediate 1 Isomer 1, Step 2 to give 16 g (crude) of 3-(4-bromobenzyl)pyrrolidine hydrochloride, Isomer 2.

[0332] LC / MS(m / z,MH+):240

[0333] Step 3': 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine, Isomer 2

[0334]

[0335] Intermediate 1 Isomer 2, Step 3' was prepared from 3-(4-bromobenzyl)pyrrolidine hydrochloride Isomer 2 following a procedure similar to that for Intermediate 1 Isomer 1, Step 3 to give 9.95 g (55%) of 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine, Isomer 2.

[0336] LC / MS(m / z,MH+):300

[0337] Intermediate 2: 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0338]

[0339] A mixture of 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (15 g, 42.82 mmol) (prepared according to WO 2017140669), Pd(PPh3)2Cl2 (1.53 g, 2.14 mmol), PPh3 (674.87 mg, 2.57 mmol), bis(pinacolato)diboron (144.08 g, 52.67 mmol) and PhOK (8.04 g, 60.80 mmol) in toluene (150 ml) was heated to 75 ° C for 1.5 hours. The yellow suspension turned orange and then brown. After cooling to room temperature, DCM (150 ml) and water (150 ml) were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of heptane / DCM from 85 / 15 to 20 / 80 to give 10.1 g (72%) of methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a white solid.

[0340] LC / MS(m / z,MH+):329

[0341] Intermediate 3: 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0342]

[0343] Intermediate 3 was prepared from 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (prepared according to WO2020 / 049153) according to a procedure similar to that for the preparation of Intermediate 2 to give 4.23 g (30% yield) of 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester as a white solid.

[0344] LC / MS(m / z,MH+):473

[0345] Intermediate 4: 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine Isomer 1 and Isomer 2

[0346]

[0347] Step 1: 3-(4-bromobenzoyl)-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester

[0348]

[0349] To a solution of commercially available tert-butyl 3-(4-bromobenzoyl)pyrrolidine-1-carboxylate (130 g, 367 mmol) in THF (1.00 L) was added LiHMDS (1 M, 514 ml) at -70°C. The reaction mixture was stirred at -70°C for 1 hour. N-(benzenesulfonyl)-N-fluoro-benzenesulfonamide (150 g, 477 mmol) in THF (500 ml) was added to the above mixture at -70°C. The reaction mixture was stirred at -70 °C for 1 hour, then poured into NH4Cl aqueous solution (500 ml), extracted with EtOAc 900 ml (3×300 ml), dried over Na2SO4, filtered and concentrated under reduced pressure, and the obtained residue was purified by flash chromatography eluting with a gradient of petroleum ether / EtOAc from 10 / 1 to 4 / 1 to give 130 g (95%) of tert-butyl 3-(4-bromobenzoyl)-3-fluoro-pyrrolidine-1-carboxylate.

[0350] LC / MS(m / z,MH+):372

[0351] Step 2: 3-[(4-Bromophenyl)-hydroxy-methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester

[0352]

[0353] At 0 ° C, NaBH4 (19.8 g, 524 mmol) was added to a solution of 3- (4- bromobenzoyl) -3- fluoro- pyrrolidine -1- carboxylic acid tert-butyl ester (130 g, 349 mmol) in MeOH (1 L). The mixture was stirred at 25 ° C for 2 hours. At 0 ° C, the reaction mixture was quenched by adding water (20 ml), and then diluted with water (400 ml) and the organic phase was removed. The water layer was extracted with EtOAc (3 × 400 ml), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain 130 g (crude) of 3- [(4- bromophenyl) -hydroxy-methyl] -3- fluoro- pyrrolidine -1- carboxylic acid tert-butyl ester as a light yellow oil.

[0354] LC / MS(m / z,MH+):374

[0355] Step 3: 3-[(4-Bromophenyl)-methylsulfanylthiocarbonyloxy-methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester

[0356]

[0357] At 10°C, NaH (13.8 g, 345 mmol, 60% purity) was added to a solution of 3-[(4-bromophenyl)-hydroxy-methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (86 g, 230 mmol) and imidazole (78.2 mg, 1.15 mmol) in THF (900 ml). The reaction mixture was stirred at 10°C for 30 minutes. Carbon disulfide (35 g, 460 mmol, 27.8 ml) was added to the mixture and the reaction mixture was stirred at 25°C for 30 minutes. Methyl iodide (58.7 g, 414 mmol, 25.8 ml) was added to the above mixture and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into NH4Cl solution (200 ml). The organic phase was separated, washed with EtOAc (3×200 ml), dried over Na 2 SO 4 , filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography eluting with a gradient of petroleum ether / EtOAc from 90 / 10 to 70 / 30 to give 102 g (96%) of 3-[(4-bromophenyl)-methylsulfanylthiocarbonyloxy-methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester as a light yellow oil.

[0358] LC / MS(m / z,MH+):374

[0359] Step 4: 3-[(4-Bromophenyl)methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester

[0360]

[0361] To a solution of 3-[(4-bromophenyl)-methylsulfanylthiocarbonyloxy-methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (25.5 g, 54.9 mmol) in toluene (250 ml) was added tributyltinane (29.6 g, 102 mmol, 26.9 ml) and AIBN (721 mg, 4.39 mmol). The reaction mixture was stirred at 90 ° C for 2 hours. After cooling to room temperature, the reaction mixture was poured into water (1 L), extracted with EtOAc (3×100 ml), dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of petroleum ether / EtOAc from 90 / 10 to 70 / 30 to give 17.25 g (88%) of 3-[(4-bromophenyl)methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester as a light yellow solid.

[0362] LC / MS(m / z,MH+):358

[0363] Step 5: 3-[(4-Bromophenyl)methyl]-3-fluoro-pyrrolidine, hydrochloride

[0364]

[0365] Step 5 of Intermediate 4 was prepared following a procedure similar to that of Intermediate 1 Isomer 1, Step 2 from 3-[(4-bromophenyl)methyl]-3-fluoro-pyrrolidine-1-carboxylic acid tert-butyl ester to give 32 g (crude) of 3-[(4-bromophenyl)methyl]-3-fluoro-pyrrolidine, hydrochloride.

[0366] LC / MS(m / z,MH+):240

[0367] Step 6: 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine

[0368]

[0369] To a solution of 3-[(4-bromophenyl)methyl]-3-fluoro-pyrrolidine, hydrochloride (32.0 g, 109 mmol) in THF (220 ml) was added NaOH (5 M, 109 ml) and 1-fluoro-3-iodo-propane (20.4 g, 109 mmol). The reaction mixture was stirred at 70° C. for 2 hours. The reaction mixture was poured into water (100 ml), extracted with EtOAc (300 ml), dried over Na2SO4, filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 98 / 02 to 90 / 10 to give 28 g (crude), which was further purified by preparative HPLC (column: Agela DuraShell C18 250x70 mm, 10 μm; mobile phase: MeCN in water (0.05% NH4OH + 10 mM NH4HCO3) gradient from 43% to 67% in 20 min) to give 12 g (35%) of 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine.

[0370] LC / MS(m / z,MH+):318

[0371] Step 7: 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine Isomer 1 and Isomer 2

[0372]

[0373] The mixture of isomers of 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine was separated by preparative SFC (column: DAICEL CHIRALPAK IG (250x30mm, 10μm); supercritical CO2 75% / MeOH 25%) to obtain 5g of 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine isomer 1 and 5g of 3-[(4-bromophenyl)methyl]-3-fluoro-1-(3-fluoropropyl)pyrrolidine isomer 2.

[0374] LC / MS(m / z,MH+):318

[0375] Intermediate 5: (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone, racemic mixture

[0376]

[0377] Step 1: (4-Bromophenyl)-pyrrolidin-3-yl-methanone, hydrochloride, racemic mixture

[0378]

[0379] Step 1 of Intermediate 5 was prepared from tert-butyl 3-(4-bromobenzoyl)pyrrolidine-1-carboxylate racemic mixture following a procedure analogous to that for the preparation of Intermediate 1 Isomer 1, Step 2, to give 76 g (crude) of (4-bromophenyl)-pyrrolidin-3-yl-methanone hydrochloride, racemic mixture.

[0380] LC / MS(m / z,MH+):254

[0381] Step 2: (4-Bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone, racemic mixture

[0382]

[0383] Step 2 of Intermediate 5 was prepared from (4-bromophenyl)-pyrrolidin-3-yl-methanone hydrochloride racemic mixture following a procedure similar to that of Step 6 of Intermediate 4 to afford 28 g (93%) of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone as a racemic mixture.

[0384] LC / MS(m / z,MH+):314

[0385] Intermediate 6: 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine Isomer 1 and Isomer 2

[0386]

[0387] Step 1: tert-Butyl 3-[(4-bromophenyl)-difluoro-methyl]pyrrolidine-1-carboxylate, racemic mixture

[0388]

[0389] To the solution of 3-(4-bromobenzoyl)pyrrolidine-1-tert-butyl formate racemic mixture (20g, 56.5mmol), bis(2-methoxyethyl)aminosulfur trifluoride BAST(100ml) was added. The mixture was stirred at 70 ℃ for 12 hours. The reaction mixture was diluted with NaHCO (1000ml) and extracted with EtOAc(300ml). The organic phase was washed with brine, dried over Na SO, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of petroleum ether / ethyl acetate from 98 / 02 to 00 / 100 to obtain 19g(89%) of 3-[(4-bromophenyl)-difluoro-methyl]pyrrolidine-1-tert-butyl formate, racemic mixture.

[0390] LC / MS(m / z,MH+):376

[0391] Step 2: 3-[(4-Bromophenyl)-difluoro-methyl]pyrrolidine hydrochloride, racemic mixture

[0392]

[0393] Step 2 of Intermediate 6 was prepared from 3-[(4-bromophenyl)-difluoro-methyl]pyrrolidine-1-carboxylic acid tert-butyl ester racemic mixture following a procedure similar to that for the preparation of Intermediate 1 Isomer 1, Step 2 to give 20 g (99%) of 3-[(4-bromophenyl)-difluoro-methyl]pyrrolidine, hydrochloride, racemic mixture.

[0394] LC / MS(m / z,MH+):276

[0395] Step 3: 3-[(4-Bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine, racemic mixture

[0396]

[0397] Step 3 of Intermediate 6 was prepared from 3-[(4-bromophenyl)-difluoro-methyl]pyrrolidine hydrochloride racemic mixture following a procedure similar to that for the preparation of Intermediate 1 Isomer 1, Step 3, to give 15 g (62%) of 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine as a racemic mixture.

[0398] LC / MS(m / z,MH+):336

[0399] Step 4: 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine Isomer 1 and Isomer 2

[0400]

[0401] The mixture of isomers of 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine was separated by preparative SFC (column: DAICEL CHIRALPAK AD (250x50mm, 10μm); supercritical CO2 85% / [0.1% NH4OH MeOH] 15%) to give 5.2g (21%) of 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine isomer 1 and 5.2g (21%) of 3-[(4-bromophenyl)-difluoro-methyl]-1-(3-fluoropropyl)pyrrolidine isomer 2.

[0402] LC / MS(m / z,MH+):336

[0403] Intermediate 7: 8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1

[0404]

[0405] Step 1: 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1

[0406]

[0407] A mixture of 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 2) (9.09 g, 27.7 mmol), 3-[(4-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine isomer 1 (Intermediate 1, isomer 1) (7.55 g, 25.1 mmol) (15 g, 52.41 mmol), Pd(dppf)Cl2 complexed with DCM (1.23 g, 1.51 mmol), Cs2CO3 (20.49 g, 62.89 mmol) in dioxane (75 ml) and water (30 ml) was heated to reflux for 4 hours. After cooling to room temperature, DCM (80 ml) and water (80 ml) were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure and the obtained residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 8.44 g (80%) of methyl 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate isomer 1 as an orange viscous oil.

[0408] LC / MS(m / z,MH+):422

[0409] Step 2: 8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0410]

[0411] To a mixture of 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 (8.58 g, 20.4 mmol) in DCM (90 ml) was added pyridinium tribromide (8.46 g, 26.5 mmol). The reaction mixture was stirred at room temperature for 2 hours. Water (100 ml) and DCM (150 ml) were added, and the pH was adjusted to 10 with a concentrated solution of NaHCO3 and K2CO3. The aqueous phase was washed three times with DCM and the collected organic phases were dried over MgSO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 6.1 g (60%) of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0412] LC / MS(m / z,MH+):500

[0413] Intermediate 8: 3-[(4-bromophenyl)methyl]-1-(3,3-difluoropropyl)pyrrolidine, isomer 1

[0414]

[0415] Step 1: 3-[(4-bromophenyl)methyl]pyrrolidine, 2,2,2-trifluoroacetic acid, isomer 1

[0416]

[0417] To a solution of tert-butyl 3-[(4-bromophenyl)methyl]pyrrolidine-1-carboxylate isomer 1 (2.11 g, 5.6 mmol) in DCM (50 ml) was added TFA (30 ml) and the mixture was stirred at room temperature for 4 hours. The solution was concentrated under vacuum and the obtained residue was treated with Et2O. The formed solid was filtered and dried to give 1.98 g (90%) of 3-[(4-bromophenyl)methyl]pyrrolidine, 2,2,2-trifluoroacetic acid, isomer 1.

[0418] LC / MS(m / z,MH+):240

[0419] Step 2: 3,3-Difluoropropyl 4-methylbenzenesulfonate

[0420]

[0421] To a solution of 3,3-difluoropropan-1-ol (500 mg, 5.2 mmol) in THF (10 ml) cooled at 0 ° C., NaH (229 mg, 5.72 mmol, 60% purity) was added, and the mixture was stirred at 0 ° C. for 1 hour. Then 4-methylbenzenesulfonyl chloride (1.04 g, 5.46 mmol) was added. After stirring at room temperature for 1 hour, a concentrated solution of NH4Cl (20 ml) was added and the mixture was extracted with EtOAc (3 × 50 ml). The combined organic phases were dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography eluting with DCM to obtain 1.03 g (79%) of 3,3-difluoropropyl 4-methylbenzenesulfonate.

[0422] LC / MS(m / z,MH+):251

[0423] Step 3: 3-[(4-bromophenyl)methyl]-1-(3,3-difluoropropyl)pyrrolidine, Isomer 1

[0424]

[0425] To a mixture of 3-[(4-bromophenyl)methyl]pyrrolidine, 2,2,2-trifluoroacetic acid, isomer 1 (1.2 g, 3.39 mmol) and KCO in MeCN (30 ml) was added 3,3-difluoropropyl 4-methylbenzenesulfonate (1.02 g, 4.07 mmol), and the mixture was heated at 80 ° C for 2 hours. The reaction mixture was quenched by adding a concentrated solution of NHCl (50 ml) and extracted with EtOAc (3×50 ml). The combined organic phases were dried over NaSO, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of DCM / EtOAc from 100 / 00 to 00 / 100 to give 607 mg (56%) of 3-[(4-bromophenyl)methyl]-1-(3,3-difluoropropyl)pyrrolidine, isomer 1.

[0426] LC / MS(m / z,MH+):318

[0427] Intermediate 9: 1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine, isomer 1

[0428]

[0429] A mixture of 3-[(4-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine isomer 1 (intermediate 1 isomer 1) (640 mg, 2.13 mmol), Pd(PPh3)2Cl2 (109 mg, 0.15 mmol), bis(pinacolato)diboron (704 mg, 2.77 mmol) and AcOK (523 mg, 5.33 mmol) in dioxane (10 ml) was heated to reflux for 2 hours. After cooling, the reaction mixture was filtered on celite. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 90 / 10 to give 270 mg (36%) of 1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine, Isomer 1.

[0430] LC / MS(m / z,MH+):348

[0431] Intermediate 10: 1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine, Isomer 1

[0432]

[0433] Intermediate 10 was prepared from 3-[(4-bromophenyl)methyl]-1-(3,3-difluoropropyl)pyrrolidine isomer 1 (Intermediate 8) following a procedure similar to that for the preparation of Intermediate 9 to give 114.8 mg (87%) of 1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine, isomer 1.

[0434] LC / MS(m / z,MH+):366

[0435] Intermediate 11: 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0436]

[0437] Step 1: 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0438]

[0439] Step 1 of Intermediate 11 was prepared from 3-[(4-bromophenyl)methyl]-1-(3,3-difluoropropyl)pyrrolidine isomer 1 (Intermediate 8) and methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (Intermediate 2) following a procedure analogous to that of Step 1 of Intermediate 7 to afford 252 mg (59%) of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate, Isomer 1.

[0440] LC / MS(m / z,MH+):440

[0441] Step 2: 8-Bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0442]

[0443] Step 2 of Intermediate 11 was prepared following a procedure similar to that of Step 2 of Intermediate 7 from 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester Isomer 1 to give 212 mg (71%) of 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0444] LC / MS(m / z,MH+):518

[0445] Intermediate 12: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0446]

[0447] Step 1: 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0448]

[0449] A mixture of 1-bromo-2,4-dichloro-benzene (890 mg, 3.94 mmol), 2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (500 mg, 2.63 mmol), CsCO (2.03 g, 10.5 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.304 g, 0.53 mmol) and tri(dibenzylideneacetone)dipalladium(0) (0.3 g, 0.53 mmol) in xylene (10 ml) was heated to reflux for 16 hours. After cooling to room temperature, water (50 ml) and EtO (50 ml) were added. The organic phase was dried over MgSO, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of cyclohexane / EtOAc from 100 / 00 to 95 / 05 to give 470 mg (42%) of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one.

[0450] LC / MS(m / z,MH+):335

[0451] Step 2: 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0452]

[0453] A mixture of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (470mg, 1.23mmol) and aluminum chloride (395mg, 2.96mmol) in toluene (8ml) was heated at 90°C for 2 hours. After cooling to room temperature, water (20ml) and EtOAc (50ml) were added. The organic phase was separated, dried over MgSO4, filtered and concentrated under reduced pressure. The obtained residue was purified by flash chromatography with a gradient elution of cyclohexane / EtOAc from 100 / 00 to 80 / 20 to obtain 165mg (42%) of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one.

[0454] LC / MS(m / z,MH+):321

[0455] Step 3: 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate

[0456]

[0457] A mixture of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (163 mg, 0.51 mmol), potassium carbonate (77 mg, 0.56 mmol) and pivaloyl chloride (67 mg, 0.56 mmol) in acetone (5 ml) was heated at 40 ° C for 1 hour. After cooling to room temperature, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 205 mg (96%) of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate.

[0458] LC / MS(m / z,MH+):405

[0459] Step 4: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0460]

[0461] Under Ar atmosphere, at -50 ° C, to a solution of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate (197 mg, 0.48 mmol) in THF (5 ml), KHMDS (1M, 0.58 ml, 0.58 mmol) was added. The mixture was stirred for 30 min, and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl) methanesulfonamide (173 mg, 0.49 mmol) was added to the resulting mixture. The reaction mixture was slowly warmed to 20 ° C and stirred for 90 minutes. The reaction mixture was quenched with saturated citric acid aqueous solution, then diluted with H2O and extracted twice with Et2O. The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 160 mg (61%) of 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate.

[0462] LC / MS(m / z,MH+):537

[0463] Intermediate 13: 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0464]

[0465] Step 1: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-yl trifluoromethanesulfonate

[0466]

[0467] 8-Hydroxy-3,4-dihydrobenzo[b]oxepin cooled at -20°C -5 (2H) -one (4.2g, 23.57mmol) (prepared according to WO 2018091153) and pyridine (2.82g, 2.89ml, 35.36mmol) in DCM (120ml) was added dropwise trifluoromethanesulfonic anhydride (8.14g, 6ml, 28.28mmol). The reaction mixture was stirred at 0 ° C for 30 minutes. Water (50ml) was added. The organic phase was separated and washed with a saturated aqueous solution of NaHCO3 (50ml). The organic phase was dried over MgSO4, filtered, and concentrated under reduced pressure to obtain 7.30g (100%) of 5-oxo-2,3,4,5-tetrahydrobenzo [b] oxepin -8-yl trifluoromethanesulfonate.

[0468] LC / MS(m / z,MH+):311

[0469] Step 2: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0470]

[0471] To 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin To a solution of -8-yl trifluoromethanesulfonate (7.4 g, 23.85 mmol) in DMF (30 ml) and MeOH (15 ml) was added DIEA (3.15 g, 4.16 ml, 23.85 mmol) and Pd(dppf)Cl2 (1.10 g, 1.43 mmol) complexed with DCM. The suspension was degassed and purged with CO three times. The mixture was stirred at 75 ° C for 2 hours under CO (5 bar). The reaction mixture was filtered through diatomaceous earth. The filtrate was diluted with water (400 ml) and extracted three times with EtOAc (300 ml). The combined organic phases were dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of heptane / ethyl acetate from 85 / 15 to 80 / 20 to obtain 4.6 g (88%) of 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0472] LC / MS(m / z,MH+):221

[0473] Step 3: 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0474]

[0475] Following a procedure similar to that of step 1 to prepare intermediate 12, 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin was prepared from Step 3 of intermediate 13 was prepared from methyl-8-carboxylate and 1-bromo-2,4-dichloro-benzene to give 1.13 g (67%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0476] LC / MS(m / z,MH+):365

[0477] Step 4: 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0478]

[0479] Following a procedure similar to that of Step 4 to prepare Intermediate 12, 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin was used. Step 4 of the preparation of intermediate 13 to give 0.48 g (31%) of 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0480] LC / MS(m / z,MH+):496

[0481] Step 5: 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0482]

[0483] Following a procedure similar to that for the preparation of Intermediate 2, 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin was prepared from Step 5 of the preparation of intermediate 13 to give 260 mg (61%) of 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0484] LC / MS(m / z,MH+):271

[0485] Intermediate 14: 3-bromo-4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylic acid methyl ester

[0486]

[0487] Step 1: 4-Oxothiochroman-7-yl trifluoromethanesulfonate

[0488]

[0489] Step 1 of Intermediate 14 was prepared following a similar procedure to that of Step 1 of Intermediate 13 from 7-hydroxythiochroman-4-one (prepared according to WO 2018091153) to give 1.14 g (33%) of 4-oxothiochroman-7-yl trifluoromethanesulfonate.

[0490] LC / MS(m / z,MH+):313

[0491] Step 2: Methyl 4-oxothiochroman-7-carboxylate

[0492]

[0493] Step 2 of Intermediate 14 was prepared following a procedure similar to that of Step 2 of Intermediate 13 from 4-oxothiochroman-7-yl trifluoromethanesulfonate to give 0.61 g (76%) of methyl 4-oxothiochroman-7-carboxylate.

[0494] LC / MS(m / z,MH+):223

[0495] Step 3: Methyl 4-(((trifluoromethyl)sulfonyl)oxy)-2H-thiochromene-7-carboxylate

[0496]

[0497] Step 3 of Intermediate 14 was prepared from methyl 4-oxothiochroman-7-carboxylate following a procedure similar to that of Step 4 of Intermediate 12 to give 199 mg (41%) of methyl 4-(((trifluoromethyl)sulfonyl)oxy)-2H-thiochromene-7-carboxylate.

[0498] LC / MS(m / z,MH+):355

[0499] Step 4: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-thiochromene-7-carboxylic acid methyl ester

[0500]

[0501] Step 4 of Intermediate 14 was prepared from methyl 4-(((trifluoromethyl)sulfonyl)oxy)-2H-thiochromene-7-carboxylate following a procedure similar to that of Intermediate 2 to afford 1 g (35%) of methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-thiochromene-7-carboxylate.

[0502] LC / MS(m / z,MH+):333

[0503] Step 5: 4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylic acid methyl ester

[0504]

[0505] Step 5 of Intermediate 14 was prepared according to a procedure similar to that of Step 1 of Intermediate 7 from methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-thiochromene-7-carboxylate and 3-[(4-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine isomer 1 (Intermediate 1, Isomer 1) to give 120 mg (47%) of methyl 4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylate, Isomer 1.

[0506] LC / MS(m / z,MH+):426

[0507] Step 6: 3-Bromo-4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylic acid methyl ester, Isomer 1

[0508]

[0509] Step 6 of Intermediate 14 was prepared following a procedure similar to that of Step 2 of Intermediate 7 from methyl 4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylate to give 140 mg (64%) of methyl 3-bromo-4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylate, Isomer 1.

[0510] LC / MS(m / z,MH+):504

[0511] Intermediate 15: 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester

[0512]

[0513] Step 1: 2-(2,4-Dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester

[0514]

[0515] Step 1 of Intermediate 15 was prepared following a procedure similar to that of Step 1 of Intermediate 12 from methyl 1-oxotetralin-6-carboxylate and 1-bromo-2,4-dichloro-benzene to give 459 mg (19%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0516] LC / MS(m / z,MH+):349

[0517] Step 2: Methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate

[0518]

[0519] Step 2 of Intermediate 15 was prepared following a procedure similar to that of Step 2 of Intermediate 12 from 2-(2,4-dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester to give 0.48 g (31%) of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate.

[0520] LC / MS(m / z,MH+):481

[0521] Intermediate 16: 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0522]

[0523] Step 1: 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0524]

[0525] Step 1 of Intermediate 16 was prepared following a procedure similar to that of Step 1 of Intermediate 12 from 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester and 1-bromo-2,4-difluoro-benzene to give 2.55 g (34%) of 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester.

[0526] LC / MS(m / z,MH+):331

[0527] Step 2: 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0528]

[0529] To a suspension of NaH (545 mg, 13.62 mmol, 60% weight purity) in Me-THF (22 ml) cooled at 5 ° C, DBU (277 mg, 0.27 ml, 1.82 mmol) was added, followed by a solution of 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydrobenzo[7]annulene-2-carboxylic acid methyl ester (3 g, 9.08 mmol) and N,N-bis(trifluoromethylsulfonyl)aniline (4.2 g, 11.81 mmol) in THF (25 ml). The cooling bath was removed to allow the temperature to warm to room temperature. A mixture of acetic acid (0.4 ml) and water (32 ml) was added dropwise, followed by water (100 ml) and EtOAc (150 ml). After decantation, the organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with DCM / heptane 50 / 50 to give 2.77 g (66%) of methyl 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0530] LC / MS(m / z,MH+):463

[0531] Step 3: 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0532]

[0533] Step 3 of Intermediate 16 was prepared from methyl 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure analogous to that of Intermediate 2 to afford 1.89 g (72%) of methyl 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0534] LC / MS(m / z,MH+):441

[0535] Intermediate 17: 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0536]

[0537] Step 1: 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0538]

[0539] Step 1 of Intermediate 17 was prepared from 1-bromo-2-methyl-4-fluoro-benzene following a procedure similar to that of Step 1 of Intermediate 12 to give 700 mg (47%) of methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate.

[0540] LC / MS(m / z,MH+):327

[0541] Step 2: 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0542]

[0543] Step 2 of Intermediate 17 was prepared from methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydrobenzo[7]annulene-2-carboxylate following a procedure analogous to that of Step 2 of Intermediate 16 to afford 7.86 g (82%) of methyl 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0544] LC / MS(m / z,MH+):459

[0545] Step 3: 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0546]

[0547] Step 3 of Intermediate 17 was prepared from methyl 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure analogous to that of Intermediate 2 to afford 3.93 g (43%) of methyl 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0548] LC / MS(m / z,MH+):437

[0549] Intermediate 18: tert-Butyl 3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate, Isomer 1

[0550]

[0551] Intermediate 18 was prepared from tert-butyl 3-(4-bromobenzyl)pyrrolidine-1-carboxylate Isomer 1 (Step 1 of Intermediate 1) following a procedure similar to that for Intermediate 9 to afford 2.53 g (74%) of tert-butyl 3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate, Isomer 1.

[0552] LC / MS(m / z,MH+):388

[0553] Intermediate 19: 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0554]

[0555] Step 1: 6-Bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0556]

[0557] To a mixture of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (9.42 g, 43.2 mmol) in DCM (400 mL) was added pyridinium tribromide (16.12 g, 45.4 mmol) in portions. The reaction mixture was stirred at room temperature overnight. Water (500 ml) and ether (1 L) were added. The organic phase was separated and washed twice with water, dried over MgSO4, filtered and concentrated under reduced pressure to give 14.4 g (90%) of 6-bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester.

[0558] LC / MS(m / z,MH+):297

[0559] Step 2: 5-Oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0560]

[0561] To a solution of 6-bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (10 g, 33.66 mmol) in acetonitrile (100 mL) was added DABCO (7.4 mL, 67.32 mmol). The reaction mixture was heated to 55 ° C for 2.5 hours under Ar. Ether and 1N HCl were added. The organic phase was separated and washed twice with water, brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was then purified by flash chromatography eluting with a mixture of cyclohexane / EtOAc 85 / 15 to give 1.88 g (26%) of 5-oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester.

[0562] LC / MS(m / z,MH+):217

[0563] Step 3: 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester, racemic mixture

[0564]

[0565] At 0°C, under Ar, to a solution of 5-oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (1.88 g, 8.6 mmol) in THF (30 mL) was added 0.328 M cuprate solution (35 mL, 11.5 mmol), which was prepared by adding 15 mL of 1.6 N solution of methyl lithium in ether to a suspension of 2.5 g of CuI (13 mmol) in 25 mL of ether at 0°C under Ar. The reaction mixture was stirred at 0°C for 30 minutes. Ether (200 mL) and 1N HCl (200 mL) were added. The organic phase was separated and the aqueous phase was extracted with ether. The combined organic phase was washed with water, dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained is then purified by flash chromatography eluting with a mixture of cyclohexane / EtOAc 95 / 5 to give 1.95 g (86%) of methyl 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate as a racemic mixture.

[0566] LC / MS(m / z,MH+):233

[0567] Step 4: 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, racemic mixture

[0568]

[0569] Step 4 of Intermediate 19 was prepared from methyl 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate following a procedure analogous to that of Step 4 of Intermediate 12 to afford 2.5 g (86%) of methyl 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a racemic mixture.

[0570] LC / MS(m / z,MH+):365

[0571] Step 5: tert-Butyl 3-(4-(3-(methoxycarbonyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulen-9-yl)benzyl)pyrrolidine-1-carboxylate, Isomer 1

[0572]

[0573] Step 5 of Intermediate 19 was prepared following a procedure analogous to that of Step 1 of Intermediate 7 from methyl 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate and tert-butyl 3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate Isomer 1 (Intermediate 18) to give 1.02 g (76%) of tert-butyl 3-(4-(3-(methoxycarbonyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-9-yl)benzyl)pyrrolidine-1-carboxylate, Isomer 1.

[0574] LC / MS(m / z,MH+):476

[0575] Step 6: 7-methyl-9-(4-(pyrrolidin-3-ylmethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, 2,2,2-trifluoroacetic acid, isomer 1

[0576]

[0577] Step 6 of Intermediate 19 was prepared from tert-butyl 3-(4-(3-(methoxycarbonyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-9-yl)benzyl)pyrrolidine-1-carboxylate Isomer 1 following a procedure analogous to that of Step 1 of Intermediate 8 to afford 753 mg (100%) of methyl 7-methyl-9-(4-(pyrrolidin-3-ylmethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate, 2,2,2-trifluoroacetic acid, Isomer 1.

[0578] LC / MS(m / z,MH+):376

[0579] Step 7: 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0580]

[0581] To a solution of 7-methyl-9-(4-(pyrrolidin-3-ylmethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, 2,2,2-trifluoroacetic acid, isomer 1 (753 mg, 1.538 mmol) in DCM (15 ml) was added NaOH (0.5 N, 7 ml) and 1-fluoro-3-iodo-propane (0.166 ml, 1.692 mmol) was added after 5 minutes. The reaction mixture was stirred at room temperature overnight. After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 90 / 10 to give 446 mg (67%) of 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0582] LC / MS(m / z,MH+):436

[0583] Step 8: 8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0584]

[0585] Step 8 of Intermediate 19 was prepared from 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester Isomer 1 following a procedure analogous to that of Step 2 of Intermediate 7 to afford 372 mg (71%) of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0586] LC / MS(m / z,MH+):514

[0587] Intermediate 20: 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1

[0588]

[0589] Step 1: 3-(4-(8-(pivaloyloxy)-2,3-dihydrobenzo[b]thiazolidine -5-yl)benzyl)pyrrolidine-1-carboxylic acid tert-butyl ester, isomer 1

[0590]

[0591] Following a procedure analogous to that of Step 1 to prepare Intermediate 7, 5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]thiazole was prepared. -8-yl pivalate (prepared according to WO 2018091153) and tert-butyl 3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate Isomer 1 (Intermediate 18) Step 1 of Intermediate 20 was prepared to give 810 mg (86%) of 3-(4-(8-(pivaloyloxy)-2,3-dihydrobenzo[b]thiazolidine)-1-carboxylate. -5-yl)benzyl)pyrrolidine-1-carboxylic acid tert-butyl ester, Isomer 1.

[0592] LC / MS(m / z,MH+):522

[0593] Step 2: 5-(4-(Pyrrolidin-3-ylmethyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ylpivalate, 2,2,2-trifluoroacetic acid, isomer 1

[0594]

[0595] Following a procedure similar to that of Step 1 to prepare Intermediate 8, 3-(4-(8-(pivaloyloxy)-2,3-dihydrobenzo[b]thiazolidine was used. Step 2 of the preparation of intermediate 20 to give 1.1 g (crude) of 5-(4-(pyrrolidin-3-ylmethyl)phenyl)-2,3-dihydrobenzo[b]thiazolidine-1-carboxylic acid tert-butyl ester isomer 1 -8-yl pivalate, 2,2,2-trifluoroacetic acid, isomer 1.

[0596] LC / MS(m / z,MH+):422

[0597] Step 3: 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-yl pivalate, isomer 1

[0598]

[0599] According to the -8-yl pivalate, 2,2,2-trifluoroacetic acid isomer 1 Procedure for preparation of step 3 of intermediate 1 A similar procedure was used to prepare step 3 of intermediate 20 to give 490 mg (66%) of 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thiamine -8-yl pivalate, isomer 1.

[0600] LC / MS(m / z,MH+):482

[0601] Step 4: 4-Bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-yl pivalate, isomer 1

[0602]

[0603] According to the method of -8-yl pivalate isomer 1 Procedure for preparation of intermediate 7, step 2 Analogous procedure was used to prepare intermediate 20, step 4 to give 360 ​​mg (63%) of 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thiazolidine -8-yl pivalate, isomer 1.

[0604] LC / MS(m / z,MH+):560

[0605] Step 5: 4-Bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1

[0606]

[0607] 4-Bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thiazole -8-yl pivalate isomer 1 (360mg, 0.64mmol) in MeOH (7ml) and NaOH 1N (2ml, 2mmpl) mixture was stirred at room temperature for 30 minutes. After adding HCl 1N (2ml), reaction mixture was concentrated under reduced pressure. In the obtained residue, DCM (60ml) and water (20ml) were added. After decantation, organic phase was dried through MgSO4, filtered and concentrated under reduced pressure to obtain 360mg (crude product) of 4-bromo-5-(4-((1-(3-fluoropropyl) pyrrolidin-3-yl) methyl) phenyl)-2,3-dihydrobenzo [b] thia -8-ol, isomer 1.

[0608] LC / MS(m / z,MH+):476

[0609] Examples

[0610] Method A:

[0611] Example 1 :8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (S) isomer

[0612]

[0613] Step 1: 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0614]

[0615] A mixture of 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 3) (101 mg, 214.75 μmol), 3-(4-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine isomer 1 (Intermediate 1, Isomer 1) (65.8 mg, 219.14 μmol), Cs2CO3 (178.5 mg, 536.9 μmol) and Pd(dppf)Cl2 complexed with DCM (18 mg, 21 μmol) in dioxane (1 ml) and water (0.4 ml) was heated to reflux for 1 hour. Water (2 ml) and DCM (5 ml) were added. After hydrophobic column decantation, the organic phase was concentrated under reduced pressure and the residue was treated on an SCX column. The obtained residue was purified by flash chromatography with a gradient elution of MeOH in DCM (100 / 0 to 95 / 05, v / v) to give 94 mg (77%) of 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1.

[0616] LC / MS(m / z,MH+):566

[0617] Step 2: 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (S) isomer

[0618]

[0619] To a solution of 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 (94 mg, 165.8 μmol) in MeOH (0.50 ml) and THF (0.5 ml) was added a solution of NaOH 1N (0.5 ml) and the reaction mixture was heated to reflux for 1 hour. After cooling, water (5 ml) and DCM (5 ml) were added and the pH was adjusted to 2 with HCl 1N. After decantation from the hydrophobic column, the organic phase was concentrated under reduced pressure and the residue was purified by SFC (Flash DCPAK B 5 μm; 250×30 mm; supercritical CO 75% / MeOH 25% / TEA 0.1% at 120 ml / min) to give 65.46 mg (71%) of 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (S) isomer.

[0620] Method B:

[0621] Example 2 :8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1

[0622]

[0623] Step 1: 8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0624]

[0625] A mixture of 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 (intermediate 7) (98 mg, 195.8 μmol), (2-chloro-4-fluoro-phenyl)boronic acid (35 mg, 203 μmol), Cs2CO3 (175 mg, 537 μmol) and Pd(dppf)Cl2 complexed with DCM (16 mg, 19 μmol) in dioxane (1 ml) and water (0.4 ml) was heated at 70° C. for 1 hour. After cooling to room temperature, water (2 ml) and DCM (5 ml) were added. After decantation from the hydrophobic column, the organic phase was concentrated under reduced pressure and the residue was treated on an SCX column to give 85 mg (79%) of 8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0626] LC / MS(m / z,MH+):550

[0627] Step 2: 8-(2-Chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1

[0628]

[0629] To a solution of 8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 (85 mg, 154.5 μmol) in MeOH (1 ml) and THF (1 ml) was added NaOH 1N (15 mg, 465 μmol) and the reaction mixture was heated to reflux for 40 minutes. After cooling, water (5 ml) and DCM (5 ml) were added and the pH was adjusted to 2 with HCl 1N. After decantation from the hydrophobic column, the organic phase was concentrated under reduced pressure and the residue was purified by SFC (Flash DCPAK B 5 μm; 250×30 mm; supercritical CO 70% / MeOH 30% / TEA 0.1% at 120 ml / min) to give 26.47 mg (30%) of 8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, Isomer 1.

[0630] Method C:

[0631] Example 36 :6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, isomer 1

[0632]

[0633] Step 1: Methyl 6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylate, Isomer 1

[0634]

[0635] A mixture of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate (Intermediate 15) (177 mg, 367 μmol), 1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]pyrrolidine isomer 1 (Intermediate 9) (98 mg, 282 μmol), Cs2CO3 (230 mg, 705 μmol) and Pd(dppf)Cl2 complexed with DCM (14 mg, 17 μmol) in dioxane (2 ml) and water (0.8 ml) was heated to 50° C. for 40 minutes. Water (2 ml) and DCM (4 ml) were added. After separation, the organic phase was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with MeOH in DCM (95 / 05, v / v) to give 33 mg (21%) of methyl 6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylate, Isomer 1.

[0636] LC / MS(m / z,MH+):552

[0637] Step 2: 6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, Isomer 1

[0638]

[0639] Step 2 of Example 36 was prepared from 6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester Isomer 1 according to a procedure similar to that of Step 2 of Preparative Example 2 to give 34 mg (100%) of 6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, Isomer 1.

[0640] Method D:

[0641] Example 3 :8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1

[0642]

[0643] Step 1: 8-(4,4-dimethylcyclohex-1-en-1-yl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0644]

[0645] Step 1 of Example 3 was prepared according to a procedure similar to that of Step 1 of Example 2 from 2-(4,4-dimethyl-1-cyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane to give 99 mg (22%) of 8-(4,4-dimethylcyclohex-1-en-1-yl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0646] LC / MS (m / z, MH+):530.

[0647] Step 2: 8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0648]

[0649] A mixture of 8-(4,4-dimethylcyclohex-1-en-1-yl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 (99 mg, 187 μmol), Pd / C 10% (21 mg, 200 μmol) in EtOH (6.5 ml) and EtOAc (4 ml) was hydrogenated at 50° C. and 5 bar of H2 for 20 hours. The reaction mixture was filtered. The filtrate was evaporated under reduced pressure and the residue was purified by column chromatography (Amylose-1 5 μM; 250×30 mm; heptane / IsoPrOH / TEA 95 / 05 / 0.1) to give 35 mg (35%) of methyl 8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate, Isomer 1.

[0650] LC / MS(m / z,MH+):532

[0651] Step 3: 8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1

[0652]

[0653] Step 3 of Example 3 was prepared from 8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 according to a procedure similar to that of Step 2 of Preparative Example 2 to give 35 mg (97%) of 8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1.

[0654] Method E:

[0655] Example 43 :4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1

[0656]

[0657] According to the procedure similar to that of Step 1 of Preparation Example 2, 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thiazol-2-yl)- ... -8-ol isomer 1 (Intermediate 20) and 2,4-dichlorophenylboronic acid were used to prepare Example 43 to give 120 mg (70%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1.

[0658] The compounds according to Table 1 above were subjected to pharmacological testing for determining their degradation effect on estrogen receptors.

[0659] Test: Estrogen receptor degradation activity

[0660] The test involves measuring the in vitro degradation activity of the compounds of Table 1a.

[0661] Degradation activity of ERα was measured using breast cancer cells in a cellular Western blot assay as described below.

[0662] MCF7 cells (ATCC) were seeded in red phenol-free MEMα medium (Invitrogen) containing 5% activated carbon dextran treated fetal bovine serum (FBS) at a concentration of 10,000 cells / 30 μL / well in 384-well microplates (collagen coated). The next day, 9 points of each compound were added to the cells in a final concentration ranging from 0.3-0.0000018 μM (Table 2) or 0.1 μM of Fulvestrant (used as a positive control) in 2.5 μL cells: 1:5 dilutions were added to the cells. 4 hours after compound addition, cells were fixed by adding 25 μL of formalin (5% formalin with a final concentration of 0.1% triton) for 10 minutes at room temperature, and then washed twice with PBS. Then, 50 μL of LI-COR blocking buffer containing 0.1% Triton was added to the plate for 30 minutes at room temperature. LI-COR blocking buffer was removed and cells were incubated overnight in a cold room with 50 μL of anti-ER rabbit monoclonal antibody (Thermo scientific MA1-39540) diluted 1:1000 in LI-COR blocking buffer containing 0.1% tween-20. Wells treated with blocking buffer but without antibody were used as background controls. The wells were washed twice with PBS (0.1% tween-20) and incubated at 37°C for 60 minutes in LI-COR (0.1% tween-20) containing goat anti-rabbit antibody Alexa 488 (1:1000) and Syto-64a DNA dye (2 μM final concentration). The cells were then washed 3 times in PBS and scanned in an ACUMEN detector (TTP-Labtech). The integrated intensity of green and red fluorescence was measured to determine the levels of ERα and DNA, respectively.

[0663] In this test, the degradation activity of estrogen receptor is determined by the concentration that degrades 50% of the estrogen receptor (or IC 50 ) is given in nM.

[0664] The % reduction in ERa levels was determined as follows: % inhibition = 100*(1-(sample - fulvestrant:DMSO-fulvestrant)).

[0665] The following Table 2 shows the estrogen receptor degradation activity results of the compounds of Table 1a tested at 0.3 μM, and demonstrates that the compounds have significant degradation activity on the estrogen receptor.

[0666] Table 2 :

[0667]

[0668]

[0669] Therefore, it is obvious that the test compound has degradation activity on estrogen receptor, IC50 is less than 1 μM and the degradation level is greater than 40%, especially greater than 45% or 50%, and for most compounds is equal to or greater than 60% or 80%. Therefore, the compound of formula (I) can be used to prepare drugs, especially drugs as degradation agents of estrogen receptor.

[0670] Test: CYP3A4 Induction Potential for ADME Characterization

[0671] The assay evaluates the potential inductive effect of the test compound on CYP3A4 gene expression in primary cultures of human hepatocytes from one or two donors with an established concentration-dependent response to the reference inducer, rifampicin.

[0672] Materials and methods

[0673] Compounds and Chemicals:

[0674] Rifampicin and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals and reagents used were obtained from common commercial sources and were of the highest commercially available grade.

[0675] Cell culture medium for cryopreserved human hepatocytes :

[0676] Thaw (UCRM TM ) and plate inoculation (UPCM TM ) medium was purchased from In Vitro ADMET Laboratories (Bethesda, MD). The medium consisted of Williams medium E with 2 mM glutamine, 0.1 μM dexamethasone, 1% ITS (10 μg / mL insulin, 5.5 μg / mL transferrin, 6.7 ng / mL sodium selenite, 50 μg / mL gentamicin (all purchased from Sigma-Aldrich).

[0677] Thawing procedures for cryopreserved human hepatocytes:

[0678] Briefly, vials containing cryopreserved cells were removed from liquid nitrogen storage, thawed in a 37°C water bath (75-90 seconds), and then rapidly poured into pre-warmed 50 mL UCRM TM The samples were centrifuged at 100 g for 10 min and then in UPCM TM The samples were rediluted in (IVAL) (so-called inoculation medium).

[0679] Human hepatocyte culture and treatment:

[0680] Before inoculation, trypan blue dye exclusion test was used to evaluate cell viability. At 37°C, in a humidified atmosphere of CO2 / air (5% / 95%), hepatocytes were seeded on 96-well plates coated with collagen I at a density of 70,000 cells / well in 100 μL of plate inoculation medium for at least 4 hours. After the cell attachment period, the plate inoculation medium was removed, and hepatocytes were treated with 100 μL / well of fresh medium for 2 consecutive days (approximately 48 hours) every day: wherein the medium contained vehicle control (0.1% DMSO) or with four concentrations of 0.3, 1, 3 and 10 μM of the research compound, or with 10 μM of the reference inducer rifampicin. All incubations were performed in duplicate.

[0681] 10 mM stock solutions of different compounds were diluted to obtain 0.3, 1 and 3 mM sub-solutions. On the day of the experiment, the stock solutions were diluted 1000-fold in the incubation / culture medium to obtain final concentrations of 0.3, 1, 3 and 10 μM.

[0682] Prior to incubation with test compounds, the quality of the hepatocyte cultures was assessed by light microscopy. The morphology of the cultured cells as well as the attachment efficiency and confluency were observed and recorded daily. Only monolayers with at least 80% confluency were used for further evaluation.

[0683] Evaluation of cytotoxicity of test compounds:

[0684] Microscopic examination of hepatocyte morphology was used to evaluate cytotoxicity during incubation for each test compound. In addition, to quantify the potential cytotoxic effects of the compounds in each experiment, cytotoxicity assessment was also performed using the Resazurin Cell Viability Assay Kit (Abcam).

[0685] Induction assay and measurement of gene expression:

[0686] After 48 h with test compound Incubation After a period, the cell culture medium was removed and the cells were lysed to release RNA for CYP3A4 gene expression assessment.CYP3A4 mRNA induction was quantified by RT-PCR analysis.

[0687] Using King Fisher TMFlex Purification System and MagMAX mirVana Total RNA Isolation Kit (Thermo Fisher Scientific, USA) were used to extract total RNA from hepatocytes. RNA was quantified by fluorescence determination using Quantifluor RNA System (Promega, USA), and cDNA was synthesized from 0.1 μg of total RNA using iScript Reverse Transcription Supermix for RT-qPCR from Biorad (France) at 42°C for 30 min. The cDNA samples were then diluted in water (1:5), and each sample of 5 μL was used for real-time PCR amplification by using the SYBR Green kit from Biorad (France). The following program was used: a denaturation step at 95°C for 30 seconds, and 40 PCR cycles (denaturation, 95°C, 10 seconds, and annealing and extension, 58°C, 1 min). In all cases, the quality of the PCR product was assessed by monitoring the fusion step at the end of the run. The human forward and reverse primer sequences used were: 5′-CCT-GGC-ACC-CAG-CAC-AAT-3′ and 5′-GGG-CCG GAC-TCG-TCA-TAC-3′ for actin, and 5′-CAC-AAA-CG-GAG-GCC-TTT-TG-3′ and 5′-ATC-CAT-GCT-GTA-GGC-CCC-AA-3′ for CYP3A4.

[0688] The Cq (quantification cycle) value was determined for single well tracing using a multivariate nonlinear regression model, and the optimal Cq value was then calculated using the model. The Cq value is inversely proportional to the amount of target nucleic acid in the sample (i.e., the lowest Cq level corresponds to the maximum amount of target nucleic acid in the sample). The Cq of the reference gene (in this study, human actin) was also used as a positive control for quantitative PCR.

[0689] Calculation and rating:

[0690] The degree of induction or E resulting from treatment with the test compound was calculated according to the following formula: max of%:

[0691]

[0692] E 化合物 : Relative fold mRNA expression after treatment with test compounds,

[0693] E 阳性对照: Relative fold mRNA expression after reference inducer (i.e., 10 μM rifampicin), E 媒介物对照 : Relative fold mRNA expression after vehicle treatment (ie, 0.1% DMSO), E is the efficiency of quantitative PCR.

[0694] Fold induction of test compounds over vehicle control mRNA expression levels can also be determined and calculated according to the following formula:

[0695] Fold induction (FI) over vehicle control = E 化合物 / E 媒介物对照 , among which the mRNA expression of E 媒介物对照 Set to 1.

[0696] The rating of the test compounds flagged as inducers was based on the E relative to rifampicin. max The percentages are listed in Table 3 below:

[0697] Table 3:

[0698] <![CDATA[E max ≤20%]]> Non-inducer - weak inducer (low risk of DDI) <![CDATA[20%<E max <45%]]> Moderate inducer (limited risk of DDI) <![CDATA[E max ≥45%]]> Inducers high in potential (high risk of DDI)

[0699] Example A: Comparative biological activity of compounds (C1) as disclosed in WO2017 / 140669 and (C2) within the scope of WO2018 / 091153

[0700] (C1) corresponds to the compound of Example 51 of WO2017 / 140669, and (C2) corresponds to a compound within the scope of WO2018 / 091153, neither of which is within the scope of the present invention.

[0701] Compound (C1) was synthesized according to Example 51 of WO2017 / 140669. Compound (C1) shows oxygen as a linker between the upper (north) phenyl moiety and the pyrrolidinyl moiety.

[0702] Compound (C2) is not specifically disclosed in WO2018 / 091153, but is generally covered. It has been synthesized according to Scheme 3a described in WO2018 / 091153. Compound (C2) shows nitrogen as a linker between the upper (north) phenyl moiety and the pyrrolidinyl moiety.

[0703] Example A.1: Preparation of compound (C2)

[0704] Compound (C2): (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0705]

[0706] Step 1: 9-(4-Hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0707]

[0708] To a mixture of 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (23.8 g, 67.94 mmol) (prepared according to WO 2017140669), (4-hydroxyphenyl)boric acid (10.85 g, 74.73 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (II) (4.48 g, 6.11 mmol) complexed with DCM in dioxane (200 ml) and water (70 ml) was added CsCO (44.32 g, 135.88 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Water (500 ml) and EtOAc (500 ml) were added. The organic phase was dried over MgSO, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a mixture of EtOAc and n-heptane (20 / 80; v / v) to give 17.36 g (87%) of methyl 9-(4-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0709] LC / MS(m / z,MH+):295

[0710] Step 2: 9-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0711]

[0712] Pyridine (2.5 mL, 30.91 mmol) and trifluoromethanesulfonic anhydride (8.55 g, 30.32 mmol) were added to a mixture of 9-(4-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (5.02 g, 17.1 mmol) in DCM (100 mL) cooled at 0 ° C. The reaction mixture was stirred at 0 ° C for 30 minutes and at room temperature for 1 hour. DCM (50 mL) and cold water (100 mL) were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure to give 7.2 g (99%) of 9-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, which was used in the next step without further purification.

[0713] LC / MS(m / z,MH+):427

[0714] Step 3: (S)-tert-butyl 3-((4-(3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)pyrrolidine-1-carboxylate

[0715]

[0716] A mixture of 9-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (2.81 g, 6.59 mmol), (S)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (2.45 g, 13.18 mmol), palladium(II) acetate (148 mg, 0.66 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.53 g, 0.92 mmol) and CsCO (6.44 g, 19.77 mmol) in dioxane (27 mL) was heated to 140 ° C for 2 hours under microwave irradiation. After cooling to room temperature, dichloromethane and water were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane / EtOAc (from 100 / 00 to 70 / 30) to give 0.8 g (26%) of (S)-tert-butyl 3-((4-(3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulen-9-yl)phenyl)amino)pyrrolidine-1-carboxylate.

[0717] Step 4: (S)-9-(4-(Pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0718]

[0719] Step 4 of compound (C2) was prepared from (S)-tert-butyl 3-((4-(3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)pyrrolidine-1-carboxylate according to a procedure similar to that for the preparation of Intermediate 1 Isomer 1, Step 2, to give 1.64 g (71%) of methyl (S)-9-(4-(pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0720] LC / MS(m / z,MH+):363

[0721] Step 5: (S)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0722]

[0723] Step 5 of compound (C2) was prepared from (S)-9-(4-(pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester according to a procedure similar to that of Step 3 of Intermediate 1 Isomer 1 to give 2.17 g (100%) of (S)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0724] Step 6: (S)-8-Bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0725]

[0726] Step 6 of compound (C2) was prepared according to a procedure similar to the procedure of Step 2 for the preparation of Intermediate 7 from methyl (S)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate to give 1.51 g (56%) of methyl (S)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0727] LC / MS(m / z,MH+):501

[0728] Step 7: (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0729]

[0730] Step 7 was prepared according to a procedure similar to that of Step 1 of Preparation Example 2 from (S)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester and 2,4-dichlorophenylboronic acid to give 182 mg (100%) of (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0731] LC / MS(m / z,MH+):567

[0732] Step 8: (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (Compound (C2))

[0733] Step 8 of compound (C2) was prepared from (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester according to a procedure similar to that of Step 2 of Preparation Example 1 to give 71 mg (100%) of (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid.

[0734] LC / MS (m / z, MH+):553.

[0735] 1H NMR(400MHz,DMSO-d6)δppm 1.44-1.58(m,1H),1.70-1.90(m,2H),2.03-2.22(m,5H),2.29(dd,J=9,5Hz,1H),2.39-2.62(m,5H ),2.76(dd,J=9,7Hz,1H),2.84-2.94(m,2H),3.68-3.86(m,1H),4.47(dt,J=47,6Hz,2H),5.75(br d,J=6Hz,1H),6.29(d,J=9Hz,2H),6.52(d,J=9Hz,2H),6.92(d,J=8Hz,1H),7.19(d,J=8Hz, 1H), 7.24-7.33 (m, 1H), 7.58 (d, J = 2Hz, 1H), 7.74 (dd, J = 8, 1.8Hz, 1H), 7.88 (d, J = 2Hz, 1H).

[0736] Example A.2: Test: Estrogen receptor degradation activity of compound (C2)

[0737] Preliminarily, compound (C2) was tested for estrogen receptor degrading activity according to the same biological conditions as described above under "Test: Estrogen Receptor Degrading Activity".

[0738] Table 4

[0739]

[0740] In Table 4, the compound (C2) tested at 0.3 μM exhibited significant degradation activity on the estrogen receptor.

[0741] In addition, as described in WO2017 / 140669, compound (C1) also showed significant degradation activity on estrogen receptors (data not shown).

[0742] Example A.3: Test: CYP 3A4 induction potential for evaluation of ADME properties of compounds of Examples 1, (C1) and (C2).

[0743] Table 5 below shows comparative data on CYP3A4 induction of the compound of the invention (Example 1) versus compounds (C1) and (C2) tested as described above.

[0744] Table 5

[0745]

[0746]

[0747] The compounds of Example 1, (C1) and (C2) are structurally close in that they present the same south part with respect to the annulene ring and the substituents, the same north part with respect to the fluoropropyl-pyrrolidine side chain, and differ only in the nature of the linker between the upper phenyl part and the pyrrolidine part. However, as shown in Table 5, the compound of Example 1 of the present invention shows no CYP3A4 induction, in other words, no CYP3A4 induction effect, and therefore shows improved ADME properties compared to compounds (C1) and (C2). Therefore, Example 1 of the present invention unexpectedly shows improved pharmacological properties compared to prior art compounds (C1) and (C2), with a low risk of inducing drug-drug interactions. Such results are not predictable by the prior art.

[0748] Example B: CYP3A4 Induction Potential of Other Compounds of the Invention

[0749] Further compounds of the invention described in Table 1a above were evaluated in the test "CYP3A4 induction potential"; the results are presented in Table 6.

[0750] Table 6

[0751]

[0752]

[0753] The CYP3A4 induction potential results in Table 6 show that various compounds of the present invention show no CYP3A4 induction, or weak or moderate CYP3A4 induction. Therefore, compared with compounds (C1) and (C2), various examples of the present invention show improved pharmacological properties with much lower risk of drug-drug interactions.

[0754] Therefore, also provided herein is a medicament comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0755] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0756] Also provided herein are compounds of formula (I) as defined above, or pharmaceutically acceptable salts thereof, for use in therapy, in particular as inhibitors and degraders of estrogen receptors, particularly showing improved pharmacological properties, typically low or limited risk of drug-drug interactions, in particular showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

[0757] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

[0758] A particular aspect is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

[0759] In embodiments, the cancer is a hormone-dependent cancer.

[0760] In another embodiment, the cancer is an estrogen receptor dependent cancer, in particular the cancer is an estrogen receptor alpha dependent cancer.

[0761] In another embodiment, the cancer is selected from breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, cervical cancer, and lung cancer, or metastases thereof.

[0762] In another embodiment, the metastasis is a brain metastasis.

[0763] In another embodiment, the cancer is breast cancer. In particular, the breast cancer is estrogen receptor positive breast cancer (ERα positive breast cancer).

[0764] In another embodiment, the cancer is resistant to anti-hormone therapy.

[0765] In further embodiments, the compounds of Formula (I) are used as single agents or in combination with other agents such as CDK4 / 6, mTOR or PI3K inhibitors.

[0766] According to another aspect, provided herein is a method of treating the above indicated pathological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an embodiment of this method of treatment, the subject is a human.

[0767] Also provided herein is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment of any of the above indicated pathological conditions, more particularly useful for the treatment of cancer.

[0768] Also provided herein are pharmaceutical compositions comprising a compound of formula (I) as an active ingredient. These pharmaceutical compositions comprise an effective dose of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0769] The excipients are selected from the customary excipients known to those skilled in the art, depending on the desired pharmaceutical form and method of administration.

[0770] In pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of the above formula (I) or its base, acid, zwitterion or salt thereof can be administered to animals and humans in a unit administration form, as a mixture with conventional pharmaceutical excipients for the treatment of the above disorders or diseases.

[0771] Suitable unit administration forms include oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration, rectal administration forms and implants. For topical application, the compounds of formula (I) can be used in creams, gels, ointments or lotions.

[0772] As an example, a unit administration form of a compound of formula (I) in the form of a tablet may comprise the following components:

[0773]

[0774]

[0775] There may be specific cases where higher or lower doses are appropriate. According to routine practice, the appropriate dose for each patient is determined by the physician according to the mode of administration and the weight and response of the patient.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in - R1 and R2 independently represent a hydrogen atom or a deuterium atom; -R3 represents a hydrogen atom, a -COOH group or a -OH group; - R3′ and R3″ independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; - R4 and R5 independently represent a hydrogen atom, a fluorine atom, a -NH2 group, a (C1-C3) alkyl group such as a methyl group, a (C1-C3) alkoxy group such as a methoxy group or an ethoxy group, or an -OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a =NOCH3 group or together with the carbon atom to which they are attached form a (C3-C5) cycloalkyl group; -R7 represents a hydrogen atom, a methyl group, an -OH group or a fluorine atom; or alternatively R4 and R7 together with the bonds to which they are attached form a cyclopropyl group which together with the adjacent pyrrolidine group yields an azaspiro[2.4]heptane; -R6 represents a group selected from the following: ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group; a fused phenyl selected from a phenyl fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl ring optionally containing unsaturation and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group and a (C1-C3)alkoxy group; ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups; ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6)alkyl group, a (C1-C6)fluoroalkyl group, a (C1-C6)alkoxy group, a (C1-C6)fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group; ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from: o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group, o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted by one or two halogen atoms or (C1-C3) alkyl; ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group; ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl or tetrahydrofuranyl, said heterocycloalkyl being saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups; ■ (C1-C6) alkyl, such as isobutyl or ethylbutyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and ■phenyl (C1-C2) alkyl, the phenyl group being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: a halogen atom; a (C1-C3) alkyl group; a (C1-C3) fluoroalkyl group; a (C1-C3) alkoxy group; a (C1-C3) fluoroalkoxy group; a cyano group; and an -OH group; -X represents -CH2-, -O-, or -S-; -Y represents -CH=, -N= or -CR"=, wherein R" represents a (C1-C3)alkyl group or a halogen atom such as a fluorine or chlorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group; - R8 independently represents a (C1-C3) alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3) fluoroalkyl group such as a trifluoromethyl group; -R9 represents a hydrogen atom or a fluorine atom; - R10 and R10' independently represent a hydrogen atom or a fluorine atom; -R11 represents a hydrogen atom, or a (C1-C3) alkyl group or a cyclopropyl group; -n is 0, 1, or 2, and -m is 0 or 1.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R1 and R2 are hydrogen atoms.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: R3 is a -COOH group or a -OH group, more particularly R3 is a -COOH group.

4. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: When m is 1, X represents -CH2- or -O-.

5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: X represents -CH2- or -O-, in particular X represents -CH2-.

6. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: R4 and R5 independently represent a hydrogen atom or a fluorine atom, and in particular, R4 and R5 both represent a hydrogen atom or R4 and R5 both represent a fluorine atom.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that: R7 represents a hydrogen atom or a fluorine atom, more particularly a hydrogen atom.

8. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein: - R4 and R5 independently represent a hydrogen atom, a -NH2 group, a (C1-C3) alkyl group such as a methyl group, a (C1-C3) alkoxy group such as a methoxy group or an ethoxy group, or an -OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a =NOCH3 group or together with the carbon atom to which they are attached form a (C3-C5) cycloalkyl group, and -R7 represents a hydrogen atom, a methyl group or an -OH group; Or alternatively R4 and R7 together with the bonds to which they are attached form a cyclopropyl group which together with the adjacent pyrrolidine group yields an azaspiro[2.4]heptane.

9. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, characterized in that: R6 represents a phenyl group which is optionally substituted by 1 to 3 substituents independently selected from: a halogen atom; a (C1-C6) alkyl group and a (C1-C6) fluoroalkyl group; in particular selected from: a fluorine atom, a chlorine atom, a methyl group and a trifluoromethyl group.

10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, characterized in that: R6 represents pyridyl, optionally substituted by 1 to 3 substituents independently selected from (C1-C6)alkoxy, more particularly methoxy.

11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, characterized in that: R6 represents a saturated or partially saturated cyclohexyl group, which is optionally substituted by 1 to 4 substituents independently selected from (C1-C3)alkyl, more particularly by 1 to 4 methyl groups.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, characterized in that: R3' and R3" both represent a hydrogen atom.

13. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, characterized in that: n is 0.

14. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: Y represents -CH=.

15. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein: R9 represents a hydrogen atom.

16. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein: R10 and R10′ both represent a hydrogen atom; or one of R10 and R10′ represents a hydrogen atom and the other represents a fluorine atom.

17. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, wherein: R11 represents a hydrogen atom or a methyl group, more particularly a hydrogen atom.

18. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 17, wherein: m is 1.

19. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in particular a hydrochloride thereof, according to any one of claims 1 to 18, characterized in that The compound is selected from the following compounds: -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (S) isomer (1), -8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(2), -8-(4,4-dimethylcyclohexyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(3), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(4), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(5), -8-(3-chloro-2-methylphenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(6), -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Carboxylic acid hydrochloride, isomer 1(7), -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Carboxylic acid hydrochloride, isomer 2(8), -8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(9), -8-(2,4-difluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(10), -8-(4,4-dimethylcyclohex-1-en-1-yl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(11), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(12), -8-(3-chloro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(13), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(6-methoxypyridin-3-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(14), -8-(3-chloro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(15), -8-(3-chloro-2-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(16), -8-(4-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(17), -8-(4-fluoro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(18), -8-(2,4-difluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(19), -8-(3-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(20), -8-(2-chloro-3-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(21), -8-(2,4-dichlorophenyl)-9-(4-((3-fluoro-1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, 2,2,2-trifluoroacetic acid isomer 2 (22), -8-(2,4-dichlorophenyl)-9-(4-((3-fluoro-1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, 2,2,2-trifluoroacetic acid, isomer 1 (23), -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (R) isomer (24), -3-(2,4-dichlorophenyl)-4-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2H-thiochromene-7-carboxylic acid hydrochloride, isomer 1(25), -8-(2,4-dichlorophenyl)-9-(4-(difluoro(1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(26), -8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(27), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-methyl-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1 (28), -8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride, isomer 1(29), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(30), -8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol hydrochloride, isomer 1(31), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-fluoro-2,6-dimethylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(32), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (33), -9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-methyl-2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(34), -8-(4-fluoro-2,6-dimethylphenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(35), -6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, isomer 1 (36), -8-(4-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(37), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1 (38), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-8-(3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(39), -8-(3-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, isomer 1(40), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1(41), -9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-7-methyl-8-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2 (42), -4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1 (43), -4-(2-chlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, isomer 1 (44).

20. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19, wherein: The compound of formula 1G -- wherein R1, R2, R3', R3", R4, R5, R6, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined in any one of claims 1 to 18, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as O-pivaloyl -- is converted to a compound of formula (I) in solution in methanol in the presence of a hydroxide ion source such as NaOH, said step optionally being preceded by a step for obtaining compound 1G, wherein a compound of formula 1F -- wherein R1, R2, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined in any one of claims 1 to 18, and R3a is as defined above -- Subjected to Suzuki coupling with a boronic acid reagent R6-B(OR')2 wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is as defined in any one of claims 1 or 9 to 11.

21. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19, wherein: The compound of formula 1Fa - wherein R1, R2, R3, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined in any one of claims 1 to 18 - undergoes a Suzuki coupling with a boronic acid reagent R6-B(OR')2 - wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is as defined in any one of claims 1 or 9 to 11, said step optionally being preceded by a step for obtaining compound 1Fa, wherein a compound of formula 1F -- wherein R1, R2, R3', R3", R4, R5, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined in any one of claims 1 to 18, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or a protected OH such as O-pivaloyl-- The conversion to compound 1Fa is carried out in solution in methanol in the presence of a hydroxide ion source such as NaOH.

22. A compound selected from the group consisting of compounds of formula 1E, 1F, 1G and 1Fa or any pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R3', R3", R4, R5, R6, R7, R8, R9, R10, R10', R11, n, m, X and Y are as defined in any one of claims 1 to 18, and R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt or a protected OH such as O-pivaloyl.

23. A compound of formula 1D or 1D' or any pharmaceutically acceptable salt thereof wherein R1, R2, R4, R5, R7, R8, R9, R10, R10′, n and Y are as defined in any one of claims 1 to 18.

24. A drug, characterized in that It comprises a compound of formula (I) according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition, characterized in that It comprises a compound of formula (I) according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

26. A compound of formula (I) according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use as an inhibitor or degrader of estrogen receptors, particularly showing improved pharmacological properties, typically low or limited risk of drug-drug interactions, especially showing no CYP3A4 induction, or weak or moderate CYP3A4 induction.

27. A compound of formula (I) according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

28. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 27, for use in the treatment of cancer.